JP2007505127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505127A5 JP2007505127A5 JP2006526272A JP2006526272A JP2007505127A5 JP 2007505127 A5 JP2007505127 A5 JP 2007505127A5 JP 2006526272 A JP2006526272 A JP 2006526272A JP 2006526272 A JP2006526272 A JP 2006526272A JP 2007505127 A5 JP2007505127 A5 JP 2007505127A5
- Authority
- JP
- Japan
- Prior art keywords
- tert
- butyl
- oxo
- naphthalen
- morpholin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 benzoisoxazolyl Chemical group 0.000 claims 47
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000005842 heteroatoms Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- 206010003246 Arthritis Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 201000008739 coronary artery disease Diseases 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 230000001404 mediated Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 201000010874 syndrome Diseases 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 2
- 208000005298 Acute Pain Diseases 0.000 claims 2
- 108009000283 Allograft Rejection Proteins 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000009137 Behcet Syndrome Diseases 0.000 claims 2
- 201000008335 Behcet's disease Diseases 0.000 claims 2
- 208000008581 Brain Disease Diseases 0.000 claims 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
- 206010007554 Cardiac failure Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000004981 Coronary Disease Diseases 0.000 claims 2
- 206010011401 Crohn's disease Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 2
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 2
- 206010013663 Drug dependence Diseases 0.000 claims 2
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 206010067410 Endotoxaemia Diseases 0.000 claims 2
- 206010015037 Epilepsy Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010019280 Heart failure Diseases 0.000 claims 2
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010022114 Injury Diseases 0.000 claims 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000003067 Myocardial Ischemia Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 206010048873 Traumatic arthritis Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000001320 atherosclerosis Diseases 0.000 claims 2
- 230000023555 blood coagulation Effects 0.000 claims 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims 2
- 201000009273 endometriosis Diseases 0.000 claims 2
- 230000020764 fibrinolysis Effects 0.000 claims 2
- 201000005569 gout Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000000302 ischemic Effects 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 201000004681 psoriasis Diseases 0.000 claims 2
- 201000001263 psoriatic arthritis Diseases 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 200000000008 restenosis Diseases 0.000 claims 2
- 201000005404 rubella Diseases 0.000 claims 2
- 201000002661 spondylitis Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000006704 ulcerative colitis Diseases 0.000 claims 2
- 230000003519 ventilatory Effects 0.000 claims 2
- FIOPRTSYUJREPD-GNVQSUKOSA-N (2Z)-2-hydroxyimino-N-[3-(methanesulfonamido)-2-methoxy-5-methylphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C1=C(C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 FIOPRTSYUJREPD-GNVQSUKOSA-N 0.000 claims 1
- XFEYYYMOFOIOMZ-MJPNWULPSA-N (2Z)-N-(3,5-ditert-butyl-2-methoxyphenyl)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C1=C(C(C)(C)C)C=C(C(C)(C)C)C(OC)=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 XFEYYYMOFOIOMZ-MJPNWULPSA-N 0.000 claims 1
- LOZJAKOSZXAODA-VYIQYICTSA-N (2Z)-N-(3-tert-butyl-1,2-oxazol-5-yl)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 LOZJAKOSZXAODA-VYIQYICTSA-N 0.000 claims 1
- NLIMXUNBSLMMQV-VYIQYICTSA-N (2Z)-N-(5-tert-butyl-1,2-oxazol-3-yl)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=N1 NLIMXUNBSLMMQV-VYIQYICTSA-N 0.000 claims 1
- LBFAETFSVGRHHJ-OLFWJLLRSA-N (2Z)-N-(5-tert-butyl-1,2-oxazol-3-yl)-2-methoxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1C(=N/OC)/C(=O)NC=1C=C(C(C)(C)C)ON=1 LBFAETFSVGRHHJ-OLFWJLLRSA-N 0.000 claims 1
- QKCDSVWYUHNEKE-RRAHZORUSA-N (2Z)-N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound S1C(C(C)(C)C)=NN=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 QKCDSVWYUHNEKE-RRAHZORUSA-N 0.000 claims 1
- ZUOWTCVJYIRIPR-MXNGAVTRSA-N (2Z)-N-(5-tert-butyl-2,3-dimethoxyphenyl)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound COC1=CC(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC ZUOWTCVJYIRIPR-MXNGAVTRSA-N 0.000 claims 1
- VJTUADNIZJWAJY-MXNGAVTRSA-N (2Z)-N-(5-tert-butyl-2-methoxy-3-methylphenyl)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound COC1=C(C)C=C(C(C)(C)C)C=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 VJTUADNIZJWAJY-MXNGAVTRSA-N 0.000 claims 1
- FZPWZRHCNJOTMU-OLFWJLLRSA-N (2Z)-N-(5-tert-butyl-2-methylpyrazol-3-yl)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 FZPWZRHCNJOTMU-OLFWJLLRSA-N 0.000 claims 1
- ILBSWLHSOGCVRE-COOPMVRXSA-N (2Z)-N-(5-tert-butylthiophen-3-yl)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 ILBSWLHSOGCVRE-COOPMVRXSA-N 0.000 claims 1
- ONMATCJBAPYTPN-GXVXDJONSA-N (2Z)-N-[5-tert-butyl-2-(3-methoxyphenyl)pyrazol-3-yl]-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound COC1=CC=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 ONMATCJBAPYTPN-GXVXDJONSA-N 0.000 claims 1
- DXRHGFRATJIZSK-MDVFONAFSA-N (2Z)-N-[5-tert-butyl-3-(ethylsulfonylamino)-2-methoxyphenyl]-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound CCS(=O)(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC DXRHGFRATJIZSK-MDVFONAFSA-N 0.000 claims 1
- YCPRWSPJNGTTTQ-MXNGAVTRSA-N (2Z)-N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)-5,6,7,8-tetrahydronaphthalen-1-yl]acetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=N/O)\C(C=1CCCCC=11)=CC=C1OCCN1CCOCC1 YCPRWSPJNGTTTQ-MXNGAVTRSA-N 0.000 claims 1
- JEGCITZKCCZDDI-MXNGAVTRSA-N (2Z)-N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 JEGCITZKCCZDDI-MXNGAVTRSA-N 0.000 claims 1
- MWQODJRMEOMZMO-DKJXEYTPSA-N (2Z)-N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-hydroxyimino-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]acetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OC1=CC=NC(N2CCOCC2)=N1 MWQODJRMEOMZMO-DKJXEYTPSA-N 0.000 claims 1
- MONCFYOVICFCLP-GPFIVKHLSA-N (2Z)-N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-methoxyimino-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]acetamide Chemical compound C=1C=C(OC=2N=C(N=CC=2)N2CCOCC2)C2=CC=CC=C2C=1C(=N/OC)/C(=O)NC1=CC(C(C)(C)C)=CC(NS(C)(=O)=O)=C1OC MONCFYOVICFCLP-GPFIVKHLSA-N 0.000 claims 1
- WZOWCBIJAFRMDW-JTHRFTPNSA-N (2Z)-N-[5-tert-butyl-4-methyl-2-(3-methylphenyl)pyrazol-3-yl]-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C=1C=CC(C)=CC=1N1N=C(C(C)(C)C)C(C)=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 WZOWCBIJAFRMDW-JTHRFTPNSA-N 0.000 claims 1
- METKAUILGHGXLG-JTHRFTPNSA-N (2Z)-N-[5-tert-butyl-4-methyl-2-(4-methylphenyl)pyrazol-3-yl]-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)(C)C)C(C)=C1NC(=O)C(=N/O)\C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 METKAUILGHGXLG-JTHRFTPNSA-N 0.000 claims 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- OVBJDDPPXDUTSM-UHFFFAOYSA-N 2-(4-bromonaphthalen-1-yl)-N-(5-tert-butyl-2-methylpyrazol-3-yl)-2-oxoacetamide Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C1=CC=C(Br)C2=CC=CC=C12 OVBJDDPPXDUTSM-UHFFFAOYSA-N 0.000 claims 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-Hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims 1
- RJEPRODGSSWEIO-UHFFFAOYSA-N 2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxo-N-(2-phenylcyclopropyl)acetamide Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1C(=O)C(=O)NC1CC1C1=CC=CC=C1 RJEPRODGSSWEIO-UHFFFAOYSA-N 0.000 claims 1
- RJEPRODGSSWEIO-RPWUZVMVSA-N 2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxo-N-[(1S,2R)-2-phenylcyclopropyl]acetamide Chemical compound C1([C@H]2C[C@@H]2NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC=CC=C1 RJEPRODGSSWEIO-RPWUZVMVSA-N 0.000 claims 1
- AEDKRWDICCQKIH-UHFFFAOYSA-N 2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxo-N-[3-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 AEDKRWDICCQKIH-UHFFFAOYSA-N 0.000 claims 1
- BSSSIIUBKDUMLB-UHFFFAOYSA-N 2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxo-N-quinolin-3-ylacetamide Chemical compound C=1N=C2C=CC=CC2=CC=1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 BSSSIIUBKDUMLB-UHFFFAOYSA-N 0.000 claims 1
- SAWFAYWCDKYSMF-UHFFFAOYSA-N 2-[4-[2-(4-acetylpiperazin-1-yl)ethoxy]naphthalen-1-yl]-N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-oxoacetamide Chemical compound C1CN(C(=O)C)CCN1CCOC(C1=CC=CC=C11)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 SAWFAYWCDKYSMF-UHFFFAOYSA-N 0.000 claims 1
- OTHGSPDUEPBQAC-UHFFFAOYSA-N 2-[4-[2-(4-acetylpiperazin-1-yl)ethoxy]naphthalen-1-yl]-N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCN(C(C)=O)CC1 OTHGSPDUEPBQAC-UHFFFAOYSA-N 0.000 claims 1
- SQGFXTIHAWNAEZ-UHFFFAOYSA-N 2-[4-[2-(4-acetylpiperazin-1-yl)ethyl]naphthalen-1-yl]-N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-oxoacetamide Chemical compound C1CN(C(=O)C)CCN1CCC(C1=CC=CC=C11)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 SQGFXTIHAWNAEZ-UHFFFAOYSA-N 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- XBTBLTVRRSBIDI-UHFFFAOYSA-N 3-[[2-(4-bromonaphthalen-1-yl)-2-oxoacetyl]amino]-5-tert-butyl-N-cyclopropyl-2-methoxybenzamide Chemical compound COC1=C(NC(=O)C(=O)C=2C3=CC=CC=C3C(Br)=CC=2)C=C(C(C)(C)C)C=C1C(=O)NC1CC1 XBTBLTVRRSBIDI-UHFFFAOYSA-N 0.000 claims 1
- UEUMWGIUABGHOM-UHFFFAOYSA-N 3-tert-butyl-5-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]-N-phenylpyrazole-1-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 UEUMWGIUABGHOM-UHFFFAOYSA-N 0.000 claims 1
- ONLRXOKCFLRNGX-UHFFFAOYSA-N 3-tert-butyl-5-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]-N-propan-2-ylpyrazole-1-carboxamide Chemical compound CC(C)NC(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ONLRXOKCFLRNGX-UHFFFAOYSA-N 0.000 claims 1
- OZAFLFDMHUWUOS-UHFFFAOYSA-N 3-tert-butyl-5-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]-N-propylpyrazole-1-carboxamide Chemical compound CCCNC(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 OZAFLFDMHUWUOS-UHFFFAOYSA-N 0.000 claims 1
- BLATWTPTWPGVIM-UHFFFAOYSA-N 3-tert-butyl-5-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]pyrazole-1-carboxamide Chemical compound NC(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 BLATWTPTWPGVIM-UHFFFAOYSA-N 0.000 claims 1
- XMZAQKDAWRWRTF-UHFFFAOYSA-N 3-tert-butyl-N-cyclohexyl-5-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]pyrazole-1-carboxamide Chemical compound C1CCCCC1NC(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 XMZAQKDAWRWRTF-UHFFFAOYSA-N 0.000 claims 1
- YWBYYTWBEXASOQ-UHFFFAOYSA-N 5-tert-butyl-2-hydroxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound NC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1O YWBYYTWBEXASOQ-UHFFFAOYSA-N 0.000 claims 1
- PMPFELVJEDKLCP-UHFFFAOYSA-N 5-tert-butyl-2-hydroxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzoic acid Chemical compound OC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1O PMPFELVJEDKLCP-UHFFFAOYSA-N 0.000 claims 1
- PWVNYDITVNDPFH-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-3-[[2-(4-methoxynaphthalen-1-yl)-2-oxoacetyl]amino]benzamide Chemical compound C12=CC=CC=C2C(OC)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=CC(C(N)=O)=C1OC PWVNYDITVNDPFH-UHFFFAOYSA-N 0.000 claims 1
- NXNPXBJSTOYMNB-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]-N-propan-2-ylbenzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NC(C)C)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 NXNPXBJSTOYMNB-UHFFFAOYSA-N 0.000 claims 1
- CJJOIIYCGGNMSM-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]-N-propylbenzamide Chemical compound CCCNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC CJJOIIYCGGNMSM-UHFFFAOYSA-N 0.000 claims 1
- JEDCYYXEEUPWRJ-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]-N-pyridin-2-ylbenzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NC=2N=CC=CC=2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 JEDCYYXEEUPWRJ-UHFFFAOYSA-N 0.000 claims 1
- UHYBNCRNWRMIMN-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(N)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 UHYBNCRNWRMIMN-UHFFFAOYSA-N 0.000 claims 1
- ZGSOLKDFJAKPJF-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzoic acid Chemical compound C1=C(C(C)(C)C)C=C(C(O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ZGSOLKDFJAKPJF-UHFFFAOYSA-N 0.000 claims 1
- WNJSCQBYRFZIPN-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-3-[[2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(N)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N2CCOCC2)=N1 WNJSCQBYRFZIPN-UHFFFAOYSA-N 0.000 claims 1
- ZZGOHUDBNBCKRL-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-N-(2-methoxyethyl)-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound COCCNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC ZZGOHUDBNBCKRL-UHFFFAOYSA-N 0.000 claims 1
- IJTBRSKMNJXHHK-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-N-(2-methylpropyl)-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NCC(C)C)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 IJTBRSKMNJXHHK-UHFFFAOYSA-N 0.000 claims 1
- DEZFDOFZCLPSHK-UHFFFAOYSA-N 5-tert-butyl-2-methoxy-N-methyl-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound CNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC DEZFDOFZCLPSHK-UHFFFAOYSA-N 0.000 claims 1
- ADZJHOICZUMRCH-GDWJVWIDSA-N 5-tert-butyl-3-[[(2Z)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetyl]amino]-N,N-dimethylthiophene-2-carboxamide Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1C(=O)N(C)C ADZJHOICZUMRCH-GDWJVWIDSA-N 0.000 claims 1
- BNVXEZKSQODNFH-QLTSDVKISA-N 5-tert-butyl-3-[[(2Z)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetyl]amino]-N-methylthiophene-2-carboxamide Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1C(=O)NC BNVXEZKSQODNFH-QLTSDVKISA-N 0.000 claims 1
- YAUGNXMCJZKJMS-WMMMYUQOSA-N 5-tert-butyl-3-[[(2Z)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetyl]amino]thiophene-2-carboxamide Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1C(N)=O YAUGNXMCJZKJMS-WMMMYUQOSA-N 0.000 claims 1
- BYKUFDIGNUZNAZ-BCJTWVECSA-N 5-tert-butyl-3-[[(2Z)-2-hydroxyimino-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]acetyl]amino]thiophene-2-carboxamide Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OC=3N=C(N=CC=3)N3CCOCC3)=CC=2)=C1C(N)=O BYKUFDIGNUZNAZ-BCJTWVECSA-N 0.000 claims 1
- ZQQQPBSWIIOITE-QLTSDVKISA-N 5-tert-butyl-3-[[(2Z)-2-methoxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetyl]amino]thiophene-2-carboxamide Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1C(=N/OC)/C(=O)NC=1C=C(C(C)(C)C)SC=1C(N)=O ZQQQPBSWIIOITE-QLTSDVKISA-N 0.000 claims 1
- DZJBBKSIKNZEHO-UHFFFAOYSA-N 5-tert-butyl-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]thiophene-2-carboxamide Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1C(N)=O DZJBBKSIKNZEHO-UHFFFAOYSA-N 0.000 claims 1
- PIPZSIIVFYUORL-UHFFFAOYSA-N 5-tert-butyl-3-[[2-[4-[[2-(dimethylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetyl]amino]thiophene-2-carboxamide Chemical compound CN(C)C1=NC=CC(NC=2C3=CC=CC=C3C(C(=O)C(=O)NC3=C(SC(=C3)C(C)(C)C)C(N)=O)=CC=2)=N1 PIPZSIIVFYUORL-UHFFFAOYSA-N 0.000 claims 1
- VKKIENWAVOLKAE-UHFFFAOYSA-N 5-tert-butyl-3-[[2-[7-chloro-4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]-2-methoxybenzamide Chemical compound C1=C(C(C)(C)C)C=C(C(N)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC(Cl)=CC=C11)=CC=C1OCCN1CCOCC1 VKKIENWAVOLKAE-UHFFFAOYSA-N 0.000 claims 1
- AXGMBPYXZNWKRP-UHFFFAOYSA-N 5-tert-butyl-3-[[2-[7-chloro-4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]-N-cyclopropyl-2-methoxybenzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NC2CC2)C(OC)=C1NC(=O)C(=O)C(C1=CC(Cl)=CC=C11)=CC=C1OCCN1CCOCC1 AXGMBPYXZNWKRP-UHFFFAOYSA-N 0.000 claims 1
- PMFXSSRMKDNFKP-UHFFFAOYSA-N 5-tert-butyl-N,N-diethyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound CCN(CC)C(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC PMFXSSRMKDNFKP-UHFFFAOYSA-N 0.000 claims 1
- ZBFZPZWKZJRNAA-UHFFFAOYSA-N 5-tert-butyl-N,N-dimethyl-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]thiophene-2-carboxamide Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1C(=O)N(C)C ZBFZPZWKZJRNAA-UHFFFAOYSA-N 0.000 claims 1
- WSFPZZBGTMELPZ-UHFFFAOYSA-N 5-tert-butyl-N-(cyclopropylmethyl)-2-methoxy-3-[[2-(4-methoxynaphthalen-1-yl)-2-oxoacetyl]amino]benzamide Chemical compound C12=CC=CC=C2C(OC)=CC=C1C(=O)C(=O)NC(C=1OC)=CC(C(C)(C)C)=CC=1C(=O)NCC1CC1 WSFPZZBGTMELPZ-UHFFFAOYSA-N 0.000 claims 1
- AAMMRMTWXMWPTO-UHFFFAOYSA-N 5-tert-butyl-N-(cyclopropylmethyl)-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NCC2CC2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 AAMMRMTWXMWPTO-UHFFFAOYSA-N 0.000 claims 1
- KZTYESNVSZDDTO-UHFFFAOYSA-N 5-tert-butyl-N-(furan-2-ylmethyl)-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NCC=2OC=CC=2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 KZTYESNVSZDDTO-UHFFFAOYSA-N 0.000 claims 1
- MRJSAFKLYNNOFK-UHFFFAOYSA-N 5-tert-butyl-N-cyclopentyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NC2CCCC2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 MRJSAFKLYNNOFK-UHFFFAOYSA-N 0.000 claims 1
- DSAKTWJMISYZBY-UHFFFAOYSA-N 5-tert-butyl-N-cyclopropyl-2-methoxy-3-[[2-(4-methoxynaphthalen-1-yl)-2-oxoacetyl]amino]benzamide Chemical compound C12=CC=CC=C2C(OC)=CC=C1C(=O)C(=O)NC(C=1OC)=CC(C(C)(C)C)=CC=1C(=O)NC1CC1 DSAKTWJMISYZBY-UHFFFAOYSA-N 0.000 claims 1
- GCBLXOYMYLHGMF-UHFFFAOYSA-N 5-tert-butyl-N-cyclopropyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NC2CC2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 GCBLXOYMYLHGMF-UHFFFAOYSA-N 0.000 claims 1
- GPLOWXPQCVMURR-UHFFFAOYSA-N 5-tert-butyl-N-cyclopropyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NC2CC2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OC(N=1)=CC=NC=1N1CCOCC1 GPLOWXPQCVMURR-UHFFFAOYSA-N 0.000 claims 1
- QHKGMTLHONSOIK-UHFFFAOYSA-N 5-tert-butyl-N-cyclopropyl-2-methoxy-3-[[2-[4-[(2-morpholin-4-ylpyridin-4-yl)amino]naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NC2CC2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC(C=1)=CC=NC=1N1CCOCC1 QHKGMTLHONSOIK-UHFFFAOYSA-N 0.000 claims 1
- USBDKNMAWIIJJP-UHFFFAOYSA-N 5-tert-butyl-N-cyclopropyl-2-methoxy-3-[[2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NC2CC2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC(N=1)=CC=NC=1N1CCOCC1 USBDKNMAWIIJJP-UHFFFAOYSA-N 0.000 claims 1
- GRKRZUXAAJPTRW-QFMPWRQOSA-N 5-tert-butyl-N-cyclopropyl-3-[[(2E)-2-hydroxyimino-2-(4-methoxynaphthalen-1-yl)acetyl]amino]-2-methoxybenzamide Chemical compound C12=CC=CC=C2C(OC)=CC=C1\C(=N/O)C(=O)NC(C=1OC)=CC(C(C)(C)C)=CC=1C(=O)NC1CC1 GRKRZUXAAJPTRW-QFMPWRQOSA-N 0.000 claims 1
- GRKRZUXAAJPTRW-QLTSDVKISA-N 5-tert-butyl-N-cyclopropyl-3-[[(2Z)-2-hydroxyimino-2-(4-methoxynaphthalen-1-yl)acetyl]amino]-2-methoxybenzamide Chemical compound C12=CC=CC=C2C(OC)=CC=C1\C(=N\O)C(=O)NC(C=1OC)=CC(C(C)(C)C)=CC=1C(=O)NC1CC1 GRKRZUXAAJPTRW-QLTSDVKISA-N 0.000 claims 1
- MKBCSKQUWQLYBL-UHFFFAOYSA-N 5-tert-butyl-N-cyclopropyl-3-[[2-hydrazinylidene-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetyl]amino]-2-methoxybenzamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)NC2CC2)C(OC)=C1NC(=O)C(=NN)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 MKBCSKQUWQLYBL-UHFFFAOYSA-N 0.000 claims 1
- QFUHRYJOZBCJIM-UHFFFAOYSA-N 5-tert-butyl-N-ethyl-2-hydroxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound CCNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1O QFUHRYJOZBCJIM-UHFFFAOYSA-N 0.000 claims 1
- TWUYACQNLSAMDB-UHFFFAOYSA-N 5-tert-butyl-N-ethyl-2-methoxy-3-[[2-(4-methoxynaphthalen-1-yl)-2-oxoacetyl]amino]benzamide Chemical compound CCNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OC)=CC=2)=C1OC TWUYACQNLSAMDB-UHFFFAOYSA-N 0.000 claims 1
- YDZSKMYIFDGHQQ-UHFFFAOYSA-N 5-tert-butyl-N-ethyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]benzamide Chemical compound CCNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC YDZSKMYIFDGHQQ-UHFFFAOYSA-N 0.000 claims 1
- DZILICBNLYXNMS-NUDFZHEQSA-N 5-tert-butyl-N-ethyl-3-[[(2Z)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetyl]amino]-2-methoxybenzamide Chemical compound CCNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC DZILICBNLYXNMS-NUDFZHEQSA-N 0.000 claims 1
- GBXWXFUUVNTYPF-UHFFFAOYSA-N 5-tert-butyl-N-ethyl-3-[[2-hydrazinylidene-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetyl]amino]-2-methoxybenzamide Chemical compound CCNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=NN)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC GBXWXFUUVNTYPF-UHFFFAOYSA-N 0.000 claims 1
- SKTSOYLBZOJGDY-UHFFFAOYSA-N 5-tert-butyl-N-methyl-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]thiophene-2-carboxamide Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1C(=O)NC SKTSOYLBZOJGDY-UHFFFAOYSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 102100010490 AMT Human genes 0.000 claims 1
- 101700056630 AMT Proteins 0.000 claims 1
- 206010000496 Acne Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000002205 Allergic Conjunctivitis Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010006451 Bronchitis Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 210000004351 Coronary Vessels Anatomy 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000004275 Demyelinating Disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010014623 Encephalopathy Diseases 0.000 claims 1
- 206010014625 Encephalopathy Diseases 0.000 claims 1
- 101710037084 GLDC Proteins 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000007386 Hepatic Encephalopathy Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 208000008459 Hyperhomocysteinemia Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- SKRDXYBATCVEMS-UHFFFAOYSA-N Isopropyl nitrite Chemical compound CC(C)ON=O SKRDXYBATCVEMS-UHFFFAOYSA-N 0.000 claims 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010025169 Lyme disease Diseases 0.000 claims 1
- 201000009035 MERRF syndrome Diseases 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 206010027260 Meningitis viral Diseases 0.000 claims 1
- 210000003097 Mucus Anatomy 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- IJSQZZCKDHTPSD-UHFFFAOYSA-N N,3-ditert-butyl-5-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]pyrazole-1-carboxamide Chemical compound CC(C)(C)NC(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 IJSQZZCKDHTPSD-UHFFFAOYSA-N 0.000 claims 1
- GOTPZIQCGDCWPL-UHFFFAOYSA-N N-(1-adamantyl)-3-tert-butyl-5-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]pyrazole-1-carboxamide Chemical compound C1C(C2)CC(C3)CC2CC13NC(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 GOTPZIQCGDCWPL-UHFFFAOYSA-N 0.000 claims 1
- RNHCBGVSDIGRRK-UHFFFAOYSA-N N-(2,3-dihydro-1H-inden-5-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C2CCCC2=CC=1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 RNHCBGVSDIGRRK-UHFFFAOYSA-N 0.000 claims 1
- FOXINTKAGJUDEG-UHFFFAOYSA-N N-(2,5-dimethylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC1=CC=C(C)C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 FOXINTKAGJUDEG-UHFFFAOYSA-N 0.000 claims 1
- GMWFGTCYWDXLPB-UHFFFAOYSA-N N-(2,5-ditert-butylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(C)(C)C1=CC=C(C(C)(C)C)C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 GMWFGTCYWDXLPB-UHFFFAOYSA-N 0.000 claims 1
- YOKZLHUWWAZSFB-UHFFFAOYSA-N N-(2,5-ditert-butylpyrazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(C)(C)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 YOKZLHUWWAZSFB-UHFFFAOYSA-N 0.000 claims 1
- ZBCUSLWZRHATJO-UHFFFAOYSA-N N-(2-acetyl-5-tert-butylpyrazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ZBCUSLWZRHATJO-UHFFFAOYSA-N 0.000 claims 1
- YZOXCRKQGXDHRT-UHFFFAOYSA-N N-(2-benzoyl-5-tert-butylpyrazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC=CC=1C(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 YZOXCRKQGXDHRT-UHFFFAOYSA-N 0.000 claims 1
- NYGPUSMTNRKKLZ-UHFFFAOYSA-N N-(2-benzyl-5-tert-butylpyrazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC=CC=1CN1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 NYGPUSMTNRKKLZ-UHFFFAOYSA-N 0.000 claims 1
- CKLVKADHWAYJPU-UHFFFAOYSA-N N-(2-methyl-5-propan-2-ylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(C)C1=CC=C(C)C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 CKLVKADHWAYJPU-UHFFFAOYSA-N 0.000 claims 1
- SUKFMRZDXZFTPQ-UHFFFAOYSA-N N-(3,4-dimethylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C)C(C)=CC=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 SUKFMRZDXZFTPQ-UHFFFAOYSA-N 0.000 claims 1
- BDNSDNJMAVRZIH-UHFFFAOYSA-N N-(3,5-ditert-butyl-2-hydroxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1O BDNSDNJMAVRZIH-UHFFFAOYSA-N 0.000 claims 1
- JDRFUOFUBPUXNG-UHFFFAOYSA-N N-(3,5-ditert-butyl-2-methoxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(C(C)(C)C)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 JDRFUOFUBPUXNG-UHFFFAOYSA-N 0.000 claims 1
- JNZWQDZJEZVRCK-UHFFFAOYSA-N N-(3,5-ditert-butylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 JNZWQDZJEZVRCK-UHFFFAOYSA-N 0.000 claims 1
- HGUYGDJAEGPRGM-UHFFFAOYSA-N N-(3-acetamido-5-tert-butyl-2-methoxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(NC(C)=O)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 HGUYGDJAEGPRGM-UHFFFAOYSA-N 0.000 claims 1
- AZMVNQYKELLYRE-UHFFFAOYSA-N N-(3-amino-5-tert-butyl-2-methoxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(N)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 AZMVNQYKELLYRE-UHFFFAOYSA-N 0.000 claims 1
- GPVLOHZKQURHEO-UHFFFAOYSA-N N-(3-amino-5-tert-butyl-2-methoxyphenyl)-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(N)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OC1=CC=NC(N2CCOCC2)=N1 GPVLOHZKQURHEO-UHFFFAOYSA-N 0.000 claims 1
- VNHDQFUAVMMOQO-UHFFFAOYSA-N N-(3-amino-5-tert-butyl-2-methoxyphenyl)-2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(N)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N2CCOCC2)=N1 VNHDQFUAVMMOQO-UHFFFAOYSA-N 0.000 claims 1
- OSOYZOXNDHHKNK-UHFFFAOYSA-N N-(3-amino-5-tert-butyl-2-methoxyphenyl)-2-[4-[[2-(dimethylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(N)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N(C)C)=N1 OSOYZOXNDHHKNK-UHFFFAOYSA-N 0.000 claims 1
- KEEOETLICJGWPP-UHFFFAOYSA-N N-(3-amino-5-tert-butyl-2-methoxyphenyl)-2-[4-[[2-(methylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CNC1=NC=CC(NC=2C3=CC=CC=C3C(C(=O)C(=O)NC=3C(=C(N)C=C(C=3)C(C)(C)C)OC)=CC=2)=N1 KEEOETLICJGWPP-UHFFFAOYSA-N 0.000 claims 1
- DMJNCMHJMLEJSQ-UHFFFAOYSA-N N-(3-amino-5-tert-butyl-2-methoxyphenyl)-2-naphthalen-1-yl-2-oxoacetamide Chemical compound COC1=C(N)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C1=CC=CC2=CC=CC=C12 DMJNCMHJMLEJSQ-UHFFFAOYSA-N 0.000 claims 1
- WPADCIKZURWWQM-NRFANRHFSA-N N-(3-amino-5-tert-butyl-2-methoxyphenyl)-2-oxo-2-[4-[[2-[[(1S)-1-phenylethyl]amino]pyrimidin-4-yl]amino]naphthalen-1-yl]acetamide Chemical compound COC1=C(N)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N[C@@H](C)C=2C=CC=CC=2)=N1 WPADCIKZURWWQM-NRFANRHFSA-N 0.000 claims 1
- NPERSMPHQQPDDJ-UHFFFAOYSA-O N-(3-amino-5-tert-butyl-2-pyridin-1-ium-1-ylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C(C(C)(C)C)=CC(N)=C([N+]=2C=CC=CC=2)C=1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 NPERSMPHQQPDDJ-UHFFFAOYSA-O 0.000 claims 1
- QNKWNESTSOPQLJ-UHFFFAOYSA-N N-(3-tert-butyl-1,2-oxazol-5-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 QNKWNESTSOPQLJ-UHFFFAOYSA-N 0.000 claims 1
- NPNGKGSEIGDQQB-UHFFFAOYSA-N N-(3-tert-butylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(C)(C)C1=CC=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 NPNGKGSEIGDQQB-UHFFFAOYSA-N 0.000 claims 1
- NDCOXQWOLXUZAP-UHFFFAOYSA-N N-(4-tert-butylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 NDCOXQWOLXUZAP-UHFFFAOYSA-N 0.000 claims 1
- CPNIJWYLPBVBKB-UHFFFAOYSA-N N-(5-tert-butyl-1,2-oxazol-3-yl)-2-(4-methoxynaphthalen-1-yl)-2-oxoacetamide Chemical compound C12=CC=CC=C2C(OC)=CC=C1C(=O)C(=O)NC=1C=C(C(C)(C)C)ON=1 CPNIJWYLPBVBKB-UHFFFAOYSA-N 0.000 claims 1
- YICSUCNKTZMZRN-UHFFFAOYSA-N N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=N1 YICSUCNKTZMZRN-UHFFFAOYSA-N 0.000 claims 1
- IWEVMKIIKJWIQT-UHFFFAOYSA-N N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]-2-oxoacetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OC=3N=C(N=CC=3)N3CCOCC3)=CC=2)=N1 IWEVMKIIKJWIQT-UHFFFAOYSA-N 0.000 claims 1
- NVGAQTKWVSNMEE-UHFFFAOYSA-N N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-(3-hydroxypropoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCCO)=CC=2)=N1 NVGAQTKWVSNMEE-UHFFFAOYSA-N 0.000 claims 1
- VKCVBNNIZZZTNA-UHFFFAOYSA-N N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[(2-morpholin-4-ylpyridin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3C=C(N=CC=3)N3CCOCC3)=CC=2)=N1 VKCVBNNIZZZTNA-UHFFFAOYSA-N 0.000 claims 1
- BIUSIFGDFPPEKM-UHFFFAOYSA-N N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3N=C(N=CC=3)N3CCOCC3)=CC=2)=N1 BIUSIFGDFPPEKM-UHFFFAOYSA-N 0.000 claims 1
- KYYDMLLJHLPDES-UHFFFAOYSA-N N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[6-(morpholin-4-ylmethyl)pyridin-3-yl]naphthalen-1-yl]-2-oxoacetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(C=3C=NC(CN4CCOCC4)=CC=3)=CC=2)=N1 KYYDMLLJHLPDES-UHFFFAOYSA-N 0.000 claims 1
- SFCGZIMIBDUXAY-UHFFFAOYSA-N N-(5-tert-butyl-1,2-oxazol-3-yl)-2-[4-[[2-(dimethylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CN(C)C1=NC=CC(NC=2C3=CC=CC=C3C(C(=O)C(=O)NC3=NOC(=C3)C(C)(C)C)=CC=2)=N1 SFCGZIMIBDUXAY-UHFFFAOYSA-N 0.000 claims 1
- GWMGXSUTAKUCQO-UHFFFAOYSA-N N-(5-tert-butyl-1H-pyrazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 GWMGXSUTAKUCQO-UHFFFAOYSA-N 0.000 claims 1
- YCXWMIKLLQMSAR-UHFFFAOYSA-N N-(5-tert-butyl-2-cyclohexylpyrazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1CCCCC1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 YCXWMIKLLQMSAR-UHFFFAOYSA-N 0.000 claims 1
- MBQPRQGGWOXWQA-UHFFFAOYSA-N N-(5-tert-butyl-2-ethoxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CCOC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 MBQPRQGGWOXWQA-UHFFFAOYSA-N 0.000 claims 1
- AIMKXNYNVHAHGE-UHFFFAOYSA-N N-(5-tert-butyl-2-hydroxy-3-methylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1O AIMKXNYNVHAHGE-UHFFFAOYSA-N 0.000 claims 1
- HRWXESULEXYMNG-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxy-3-methylphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(C)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 HRWXESULEXYMNG-UHFFFAOYSA-N 0.000 claims 1
- GHVRAPBHFZUHHM-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 GHVRAPBHFZUHHM-UHFFFAOYSA-N 0.000 claims 1
- FNHGFASCDFXJKF-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OC1=CC=NC(N2CCOCC2)=N1 FNHGFASCDFXJKF-UHFFFAOYSA-N 0.000 claims 1
- RBLJRIREZZLBNG-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-[4-[(2-morpholin-4-ylpyridin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N2CCOCC2)=C1 RBLJRIREZZLBNG-UHFFFAOYSA-N 0.000 claims 1
- HPQWLHXNYHBCEA-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N2CCOCC2)=N1 HPQWLHXNYHBCEA-UHFFFAOYSA-N 0.000 claims 1
- LLIBZCPHHJQNGM-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-[4-[6-(morpholin-4-ylmethyl)pyridin-3-yl]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1C(C=N1)=CC=C1CN1CCOCC1 LLIBZCPHHJQNGM-UHFFFAOYSA-N 0.000 claims 1
- VGHGGKXNJJLKBG-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-[4-[6-(oxan-4-ylamino)pyridin-3-yl]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1C(C=N1)=CC=C1NC1CCOCC1 VGHGGKXNJJLKBG-UHFFFAOYSA-N 0.000 claims 1
- XIMXXKWKAWOWGF-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-[4-[[2-(dimethylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N(C)C)=N1 XIMXXKWKAWOWGF-UHFFFAOYSA-N 0.000 claims 1
- ZJUMPNTYBZULBY-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-[4-[[2-(methylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CNC1=NC=CC(NC=2C3=CC=CC=C3C(C(=O)C(=O)NC=3C(=CC=C(C=3)C(C)(C)C)OC)=CC=2)=N1 ZJUMPNTYBZULBY-UHFFFAOYSA-N 0.000 claims 1
- QEVCGUAHNFTMBY-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-naphthalen-1-yl-2-oxoacetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C1=CC=CC2=CC=CC=C12 QEVCGUAHNFTMBY-UHFFFAOYSA-N 0.000 claims 1
- MYMSGNONGAITCI-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-oxo-2-(4-pyridin-3-ylnaphthalen-1-yl)acetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1C1=CC=CN=C1 MYMSGNONGAITCI-UHFFFAOYSA-N 0.000 claims 1
- BCCDBNZRUVAZPR-UHFFFAOYSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-oxo-2-[4-(2-piperidin-1-ylpyrimidin-4-yl)oxynaphthalen-1-yl]acetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OC1=CC=NC(N2CCCCC2)=N1 BCCDBNZRUVAZPR-UHFFFAOYSA-N 0.000 claims 1
- ZQQQDKRLZGKCNS-QFIPXVFZSA-N N-(5-tert-butyl-2-methoxyphenyl)-2-oxo-2-[4-[[2-[[(1S)-1-phenylethyl]amino]pyrimidin-4-yl]amino]naphthalen-1-yl]acetamide Chemical compound COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N[C@@H](C)C=2C=CC=CC=2)=N1 ZQQQDKRLZGKCNS-QFIPXVFZSA-N 0.000 claims 1
- OJWCEYVLTUKVFG-UHFFFAOYSA-N N-(5-tert-butyl-2-methylpyrazol-3-yl)-2-(4-methoxynaphthalen-1-yl)-2-oxoacetamide Chemical compound C12=CC=CC=C2C(OC)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C OJWCEYVLTUKVFG-UHFFFAOYSA-N 0.000 claims 1
- ONQABYHFFGWLSD-UHFFFAOYSA-N N-(5-tert-butyl-2-methylpyrazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ONQABYHFFGWLSD-UHFFFAOYSA-N 0.000 claims 1
- RYJYCJAEOMXCMT-UHFFFAOYSA-N N-(5-tert-butyl-2-methylpyrazol-3-yl)-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]-2-oxoacetamide Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OC1=CC=NC(N2CCOCC2)=N1 RYJYCJAEOMXCMT-UHFFFAOYSA-N 0.000 claims 1
- KQCSYRHCAKWBAC-UHFFFAOYSA-N N-(5-tert-butyl-2-methylpyrazol-3-yl)-2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N2CCOCC2)=N1 KQCSYRHCAKWBAC-UHFFFAOYSA-N 0.000 claims 1
- DUAYQVWFLWXVEU-UHFFFAOYSA-N N-(5-tert-butyl-2-methylpyrazol-3-yl)-2-[4-[(4-morpholin-4-ylpyrimidin-2-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=NC=CC(N2CCOCC2)=N1 DUAYQVWFLWXVEU-UHFFFAOYSA-N 0.000 claims 1
- ZTWYEISFWJJJTC-UHFFFAOYSA-N N-(5-tert-butyl-2-methylpyrazol-3-yl)-2-[4-[6-(morpholin-4-ylmethyl)pyridin-3-yl]naphthalen-1-yl]-2-oxoacetamide Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1C(C=N1)=CC=C1CN1CCOCC1 ZTWYEISFWJJJTC-UHFFFAOYSA-N 0.000 claims 1
- VACQJQSMWKNDEF-UHFFFAOYSA-N N-(5-tert-butyl-2-naphthalen-1-ylpyrazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC2=CC=CC=C2C=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 VACQJQSMWKNDEF-UHFFFAOYSA-N 0.000 claims 1
- APFPMAPUIYGXQN-UHFFFAOYSA-N N-(5-tert-butyl-2-phenylpyrazol-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 APFPMAPUIYGXQN-UHFFFAOYSA-N 0.000 claims 1
- NIJLJZXZICPWHI-UHFFFAOYSA-N N-(5-tert-butyl-2-propan-2-yloxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(C)OC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 NIJLJZXZICPWHI-UHFFFAOYSA-N 0.000 claims 1
- JQUTUFUVQNZOGP-UHFFFAOYSA-N N-(5-tert-butyl-3-chloro-2-methoxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(Cl)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 JQUTUFUVQNZOGP-UHFFFAOYSA-N 0.000 claims 1
- ZMGAZIPLMZBPFG-UHFFFAOYSA-N N-(5-tert-butylthiophen-3-yl)-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 ZMGAZIPLMZBPFG-UHFFFAOYSA-N 0.000 claims 1
- BHTQSXPVZKCWAS-UHFFFAOYSA-N N-[2-(3-aminophenyl)-5-tert-butylpyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(N)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 BHTQSXPVZKCWAS-UHFFFAOYSA-N 0.000 claims 1
- LXFJUECJZPBGLM-UHFFFAOYSA-N N-[2-(4-acetylphenyl)-5-tert-butylpyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C(=O)C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 LXFJUECJZPBGLM-UHFFFAOYSA-N 0.000 claims 1
- GEOIGXFUOOWIQB-UHFFFAOYSA-N N-[2-(4-aminophenyl)-5-tert-butylpyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(N)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 GEOIGXFUOOWIQB-UHFFFAOYSA-N 0.000 claims 1
- CTWPDJHKHQCSSD-UHFFFAOYSA-N N-[2-(4-bromophenyl)-5-tert-butylpyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(Br)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 CTWPDJHKHQCSSD-UHFFFAOYSA-N 0.000 claims 1
- ZEXLFVYJIOIASK-UHFFFAOYSA-N N-[2-(4-methylphenyl)-5-propan-2-ylpyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ZEXLFVYJIOIASK-UHFFFAOYSA-N 0.000 claims 1
- NXGIMXZBMNXYNE-UHFFFAOYSA-N N-[2-(benzenesulfonyl)-5-tert-butylpyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 NXGIMXZBMNXYNE-UHFFFAOYSA-N 0.000 claims 1
- KZWSLFRPOVRNHH-UHFFFAOYSA-N N-[2-bromo-5-(trifluoromethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound FC(F)(F)C1=CC=C(Br)C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 KZWSLFRPOVRNHH-UHFFFAOYSA-N 0.000 claims 1
- HGADCMCJIWMZTQ-UHFFFAOYSA-N N-[2-chloro-5-(trifluoromethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound FC(F)(F)C1=CC=C(Cl)C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 HGADCMCJIWMZTQ-UHFFFAOYSA-N 0.000 claims 1
- IHNCYNCUEZUHRG-UHFFFAOYSA-N N-[2-hydroxy-3,5-bis(2-methylbutan-2-yl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CCC(C)(C)C1=CC(C(C)(C)CC)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1O IHNCYNCUEZUHRG-UHFFFAOYSA-N 0.000 claims 1
- HXDXBVWDXXFXEY-UHFFFAOYSA-N N-[2-methoxy-3,5-bis(2-methylbutan-2-yl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CCC(C)(C)C1=CC(C(C)(C)CC)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC HXDXBVWDXXFXEY-UHFFFAOYSA-N 0.000 claims 1
- MIDKJWWNZVBXDK-UHFFFAOYSA-N N-[2-methoxy-5-(2-phenylpropan-2-yl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=C(C(C)(C)C=2C=CC=CC=2)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 MIDKJWWNZVBXDK-UHFFFAOYSA-N 0.000 claims 1
- NJEWXMSBYWCRAV-UHFFFAOYSA-N N-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 NJEWXMSBYWCRAV-UHFFFAOYSA-N 0.000 claims 1
- IZWKJTXMNKXBJU-UHFFFAOYSA-N N-[3-(4-acetylpiperazine-1-carbonyl)-5-tert-butyl-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 IZWKJTXMNKXBJU-UHFFFAOYSA-N 0.000 claims 1
- DPJYLCHHHMUFNM-UHFFFAOYSA-N N-[3-(benzenesulfonamido)-5-tert-butyl-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(=O)(=O)C=2C=CC=CC=2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 DPJYLCHHHMUFNM-UHFFFAOYSA-N 0.000 claims 1
- TWFOYJQVKPNAHA-UHFFFAOYSA-N N-[3-(benzylsulfonylamino)-5-tert-butyl-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(=O)(=O)CC=2C=CC=CC=2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 TWFOYJQVKPNAHA-UHFFFAOYSA-N 0.000 claims 1
- LXSKFXJXYUJSRL-UHFFFAOYSA-N N-[3-(methanesulfonamido)-2-methoxy-5-methylphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 LXSKFXJXYUJSRL-UHFFFAOYSA-N 0.000 claims 1
- VKYYOAMSXWQPHF-UHFFFAOYSA-N N-[3-(methanesulfonamido)-5-(trifluoromethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound FC(F)(F)C1=CC(NS(=O)(=O)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 VKYYOAMSXWQPHF-UHFFFAOYSA-N 0.000 claims 1
- XIXJYJPHMQKVFI-UHFFFAOYSA-N N-[3-[(2-amino-2-oxoethyl)-(benzenesulfonyl)amino]-5-tert-butyl-2-methoxyphenyl]-2-naphthalen-1-yl-2-oxoacetamide Chemical compound COC1=C(NC(=O)C(=O)C=2C3=CC=CC=C3C=CC=2)C=C(C(C)(C)C)C=C1N(CC(N)=O)S(=O)(=O)C1=CC=CC=C1 XIXJYJPHMQKVFI-UHFFFAOYSA-N 0.000 claims 1
- AUJYDDPHQWCTCX-UHFFFAOYSA-N N-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]-5-tert-butyl-2-methoxyphenyl]-2-naphthalen-1-yl-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(N(CC(N)=O)S(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C1=CC=CC2=CC=CC=C12 AUJYDDPHQWCTCX-UHFFFAOYSA-N 0.000 claims 1
- NFMJYKDPDWCADA-UHFFFAOYSA-N N-[3-[(2-amino-2-oxoethyl)-propylsulfonylamino]-5-tert-butyl-2-methoxyphenyl]-2-naphthalen-1-yl-2-oxoacetamide Chemical compound CCCS(=O)(=O)N(CC(N)=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C=CC=2)=C1OC NFMJYKDPDWCADA-UHFFFAOYSA-N 0.000 claims 1
- NWVBFFJKNGLBOI-UHFFFAOYSA-N N-[3-amino-5-(trifluoromethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound FC(F)(F)C1=CC(N)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 NWVBFFJKNGLBOI-UHFFFAOYSA-N 0.000 claims 1
- KMXQHQZTCSEHMU-UHFFFAOYSA-N N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(Br)C(C(F)(F)F)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 KMXQHQZTCSEHMU-UHFFFAOYSA-N 0.000 claims 1
- SRFKLPOUEZUSRO-UHFFFAOYSA-N N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(4-methoxynaphthalen-1-yl)-2-oxoacetamide Chemical compound C12=CC=CC=C2C(OC)=CC=C1C(=O)C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 SRFKLPOUEZUSRO-UHFFFAOYSA-N 0.000 claims 1
- LFBNKYGQNYBSCH-UHFFFAOYSA-N N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 LFBNKYGQNYBSCH-UHFFFAOYSA-N 0.000 claims 1
- JBUZPAYYXQPNRC-UHFFFAOYSA-N N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 JBUZPAYYXQPNRC-UHFFFAOYSA-N 0.000 claims 1
- YPEIYUPJEOHVTR-UHFFFAOYSA-N N-[4-tert-butyl-6-(trifluoromethyl)pyrimidin-2-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(C)(C)C1=CC(C(F)(F)F)=NC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=N1 YPEIYUPJEOHVTR-UHFFFAOYSA-N 0.000 claims 1
- QXLLQROHJOPELG-UHFFFAOYSA-N N-[5-(2-methylpentan-2-yl)-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(C)C=CC=1N1N=C(C(C)(C)CCC)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 QXLLQROHJOPELG-UHFFFAOYSA-N 0.000 claims 1
- GHBKVEBOASMNCE-UHFFFAOYSA-N N-[5-tert-butyl-2-(2,3-dichlorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(Cl)=C(Cl)C=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 GHBKVEBOASMNCE-UHFFFAOYSA-N 0.000 claims 1
- OBYUUXIPVPQYMO-UHFFFAOYSA-N N-[5-tert-butyl-2-(2,3-dimethylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC1=CC=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1C OBYUUXIPVPQYMO-UHFFFAOYSA-N 0.000 claims 1
- XIKHADGAOSJYHC-UHFFFAOYSA-N N-[5-tert-butyl-2-(2,4-dichlorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 XIKHADGAOSJYHC-UHFFFAOYSA-N 0.000 claims 1
- MBVXHAXQHPGQMA-UHFFFAOYSA-N N-[5-tert-butyl-2-(2,4-difluorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(F)C=C(F)C=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 MBVXHAXQHPGQMA-UHFFFAOYSA-N 0.000 claims 1
- JECNCEWOLYWOPG-UHFFFAOYSA-N N-[5-tert-butyl-2-(2,5-dichlorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C(Cl)=CC=C(Cl)C=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 JECNCEWOLYWOPG-UHFFFAOYSA-N 0.000 claims 1
- HFZRUOGIEIPCAC-UHFFFAOYSA-N N-[5-tert-butyl-2-(2,5-difluorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C(F)=CC=C(F)C=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 HFZRUOGIEIPCAC-UHFFFAOYSA-N 0.000 claims 1
- WDJSELWMGSEBTI-UHFFFAOYSA-N N-[5-tert-butyl-2-(2,5-dimethylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC1=CC=C(C)C(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 WDJSELWMGSEBTI-UHFFFAOYSA-N 0.000 claims 1
- OOLGXTRXXACWEA-UHFFFAOYSA-N N-[5-tert-butyl-2-(2-chlorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC=C(Cl)C=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 OOLGXTRXXACWEA-UHFFFAOYSA-N 0.000 claims 1
- HKNRETMMTGULKN-UHFFFAOYSA-N N-[5-tert-butyl-2-(2-methylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC1=CC=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 HKNRETMMTGULKN-UHFFFAOYSA-N 0.000 claims 1
- ACLZWLPFORXEEN-UHFFFAOYSA-N N-[5-tert-butyl-2-(2-methylpropoxy)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC(C)COC1=CC=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ACLZWLPFORXEEN-UHFFFAOYSA-N 0.000 claims 1
- YVXHDLGWWKWCRW-UHFFFAOYSA-N N-[5-tert-butyl-2-(2-phenylacetyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC=CC=1CC(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 YVXHDLGWWKWCRW-UHFFFAOYSA-N 0.000 claims 1
- UVYUUWPDALWLDI-UHFFFAOYSA-N N-[5-tert-butyl-2-(3,4-dichlorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 UVYUUWPDALWLDI-UHFFFAOYSA-N 0.000 claims 1
- OHLWVBVKQCVLQB-UHFFFAOYSA-N N-[5-tert-butyl-2-(3,4-dimethylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C)C(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 OHLWVBVKQCVLQB-UHFFFAOYSA-N 0.000 claims 1
- CAUOYLPQRLMXQE-UHFFFAOYSA-N N-[5-tert-butyl-2-(3,5-dichlorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C(Cl)=CC(Cl)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 CAUOYLPQRLMXQE-UHFFFAOYSA-N 0.000 claims 1
- BALVHKZKXQVVDP-UHFFFAOYSA-N N-[5-tert-butyl-2-(3,5-dimethylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC1=CC(C)=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 BALVHKZKXQVVDP-UHFFFAOYSA-N 0.000 claims 1
- FUSOJPSGILWHLE-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-chloro-4-fluorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(F)C(Cl)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 FUSOJPSGILWHLE-UHFFFAOYSA-N 0.000 claims 1
- GKLSQOGLWMKREW-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-chloro-4-methylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(Cl)C(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 GKLSQOGLWMKREW-UHFFFAOYSA-N 0.000 claims 1
- CXIVVVQOPYUYMM-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-chlorobenzoyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(Cl)=CC=1C(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 CXIVVVQOPYUYMM-UHFFFAOYSA-N 0.000 claims 1
- ICQDHRCTZUGWLT-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(Cl)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ICQDHRCTZUGWLT-UHFFFAOYSA-N 0.000 claims 1
- QIRFKOKMUUQCDG-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-chlorophenyl)sulfonylpyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(Cl)=CC=1S(=O)(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 QIRFKOKMUUQCDG-UHFFFAOYSA-N 0.000 claims 1
- PWDHTGNLCDFXCC-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-cyanophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(C#N)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 PWDHTGNLCDFXCC-UHFFFAOYSA-N 0.000 claims 1
- BRDAZKBHNVQTRS-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-fluoro-4-methylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(F)C(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 BRDAZKBHNVQTRS-UHFFFAOYSA-N 0.000 claims 1
- QBOMNQTZLFCRKK-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-fluorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(F)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 QBOMNQTZLFCRKK-UHFFFAOYSA-N 0.000 claims 1
- KXIBNDFIIHQGLF-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-methoxyphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 KXIBNDFIIHQGLF-UHFFFAOYSA-N 0.000 claims 1
- WLHZOCKYDCYEKR-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-methoxyphenyl)pyrazol-3-yl]-2-[4-[(2-morpholin-4-ylpyridin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3C=C(N=CC=3)N3CCOCC3)=CC=2)=C1 WLHZOCKYDCYEKR-UHFFFAOYSA-N 0.000 claims 1
- WLOQSZJAQOBRFE-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-methoxyphenyl)pyrazol-3-yl]-2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3N=C(N=CC=3)N3CCOCC3)=CC=2)=C1 WLOQSZJAQOBRFE-UHFFFAOYSA-N 0.000 claims 1
- LHVPJEKMQKNYJU-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-methoxyphenyl)pyrazol-3-yl]-2-[4-[[2-(dimethylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=CC=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3N=C(N=CC=3)N(C)C)=CC=2)=C1 LHVPJEKMQKNYJU-UHFFFAOYSA-N 0.000 claims 1
- IPWSPNZYVWESPU-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-methylbenzoyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC1=CC=CC(C(=O)N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 IPWSPNZYVWESPU-UHFFFAOYSA-N 0.000 claims 1
- NDJIGWBGLINRRI-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-methylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CC1=CC=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1 NDJIGWBGLINRRI-UHFFFAOYSA-N 0.000 claims 1
- KLDUJDFUGLGEQK-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-methylphenyl)pyrazol-3-yl]-2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CC1=CC=CC(N2C(=CC(=N2)C(C)(C)C)NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3N=C(N=CC=3)N3CCOCC3)=CC=2)=C1 KLDUJDFUGLGEQK-UHFFFAOYSA-N 0.000 claims 1
- VYCTWZSVKIKCET-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-methylphenyl)pyrazol-3-yl]-2-[4-[2-(dimethylamino)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C12=CC=CC=C2C(OCCN(C)C)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=CC(C)=C1 VYCTWZSVKIKCET-UHFFFAOYSA-N 0.000 claims 1
- FJHLYOLONUOETL-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-methylsulfonylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(S(C)(=O)=O)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 FJHLYOLONUOETL-UHFFFAOYSA-N 0.000 claims 1
- USHSANZZMUSRKA-UHFFFAOYSA-N N-[5-tert-butyl-2-(3-nitrophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC([N+]([O-])=O)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 USHSANZZMUSRKA-UHFFFAOYSA-N 0.000 claims 1
- GWUYPCRHNKUROU-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-chlorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 GWUYPCRHNKUROU-UHFFFAOYSA-N 0.000 claims 1
- UXGXXMXYEYSJOE-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-cyanophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(C#N)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 UXGXXMXYEYSJOE-UHFFFAOYSA-N 0.000 claims 1
- DMZSWEMXIXYFDJ-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-fluorophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(F)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 DMZSWEMXIXYFDJ-UHFFFAOYSA-N 0.000 claims 1
- VZXNRXHWROWZCV-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methoxyphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(OC)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 VZXNRXHWROWZCV-UHFFFAOYSA-N 0.000 claims 1
- LNYBFILPLMPHNN-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylbenzoyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1C(=O)N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 LNYBFILPLMPHNN-UHFFFAOYSA-N 0.000 claims 1
- JDBNVWJZMZATCK-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[3-chloro-4-(2-morpholin-4-ylethoxy)phenyl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C=C(Cl)C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 JDBNVWJZMZATCK-UHFFFAOYSA-N 0.000 claims 1
- IFRGORKZXUPBFK-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-(2-imidazol-1-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3C=NC=C3)=CC=2)=CC(C(C)(C)C)=N1 IFRGORKZXUPBFK-UHFFFAOYSA-N 0.000 claims 1
- KTWLENWFTNYHHC-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-(2-imidazol-1-ylethyl)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(CCN3C=NC=C3)=CC=2)=CC(C(C)(C)C)=N1 KTWLENWFTNYHHC-UHFFFAOYSA-N 0.000 claims 1
- MEVNIFZDIFKOCZ-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MEVNIFZDIFKOCZ-UHFFFAOYSA-N 0.000 claims 1
- GTAMXPWLQGWMGL-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OC=3N=C(N=CC=3)N3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 GTAMXPWLQGWMGL-UHFFFAOYSA-N 0.000 claims 1
- KGIRDMICAOKILV-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[(2-morpholin-4-ylpyridin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3C=C(N=CC=3)N3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 KGIRDMICAOKILV-UHFFFAOYSA-N 0.000 claims 1
- GTSQQRRXPFYYRT-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3N=C(N=CC=3)N3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 GTSQQRRXPFYYRT-UHFFFAOYSA-N 0.000 claims 1
- XQFWBRUDDBDWAD-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[2-(1,4-oxazepan-4-yl)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCCC3)=CC=2)=CC(C(C)(C)C)=N1 XQFWBRUDDBDWAD-UHFFFAOYSA-N 0.000 claims 1
- OXYPFEXCUCDTOE-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[2-(2,6-dimethylmorpholin-4-yl)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1C(C)OC(C)CN1CCOC(C1=CC=CC=C11)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 OXYPFEXCUCDTOE-UHFFFAOYSA-N 0.000 claims 1
- BTCVSQNKIXZREL-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[2-(2,6-dimethylmorpholin-4-yl)ethyl]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1C(C)OC(C)CN1CCC(C1=CC=CC=C11)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 BTCVSQNKIXZREL-UHFFFAOYSA-N 0.000 claims 1
- WBPZRDCPXMTWRJ-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[2-(4-methylpiperazin-1-yl)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1CN(C)CCN1CCOC(C1=CC=CC=C11)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 WBPZRDCPXMTWRJ-UHFFFAOYSA-N 0.000 claims 1
- UPGUODJRUQPNGU-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[2-(4-methylpiperazin-1-yl)ethyl]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1CN(C)CCN1CCC(C1=CC=CC=C11)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 UPGUODJRUQPNGU-UHFFFAOYSA-N 0.000 claims 1
- OXYPFEXCUCDTOE-DNQXCXABSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[2-[(2R,6R)-2,6-dimethylmorpholin-4-yl]ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1[C@@H](C)O[C@H](C)CN1CCOC(C1=CC=CC=C11)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 OXYPFEXCUCDTOE-DNQXCXABSA-N 0.000 claims 1
- OXYPFEXCUCDTOE-PSWAGMNNSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1[C@@H](C)O[C@@H](C)CN1CCOC(C1=CC=CC=C11)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 OXYPFEXCUCDTOE-PSWAGMNNSA-N 0.000 claims 1
- SZPGGSJYCLQLBL-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[4-[6-(morpholin-4-ylmethyl)pyridin-3-yl]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(C=3C=NC(CN4CCOCC4)=CC=3)=CC=2)=CC(C(C)(C)C)=N1 SZPGGSJYCLQLBL-UHFFFAOYSA-N 0.000 claims 1
- KMJJCZVUYDIXTL-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-[7-chloro-4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC(Cl)=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 KMJJCZVUYDIXTL-UHFFFAOYSA-N 0.000 claims 1
- FZVFQDSBFGYBDB-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-oxo-2-[4-(2-pyridin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCC=3C=CN=CC=3)=CC=2)=CC(C(C)(C)C)=N1 FZVFQDSBFGYBDB-UHFFFAOYSA-N 0.000 claims 1
- INTCILADWQVLGH-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-oxo-2-[4-(2-thiomorpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCSCC3)=CC=2)=CC(C(C)(C)C)=N1 INTCILADWQVLGH-UHFFFAOYSA-N 0.000 claims 1
- SYPFVYGKNNXQLN-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-oxo-2-[4-(3-pyridin-4-ylpropoxy)naphthalen-1-yl]acetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCCC=3C=CN=CC=3)=CC=2)=CC(C(C)(C)C)=N1 SYPFVYGKNNXQLN-UHFFFAOYSA-N 0.000 claims 1
- CVWQTWQGPQVJIW-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-oxo-2-[4-[2-(3-oxopiperazin-1-yl)ethoxy]naphthalen-1-yl]acetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CC(=O)NCC3)=CC=2)=CC(C(C)(C)C)=N1 CVWQTWQGPQVJIW-UHFFFAOYSA-N 0.000 claims 1
- MIVYVLSKXXQSAE-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-2-oxo-2-[4-[2-(3-oxopiperazin-1-yl)ethyl]naphthalen-1-yl]acetamide Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(CCN3CC(=O)NCC3)=CC=2)=CC(C(C)(C)C)=N1 MIVYVLSKXXQSAE-UHFFFAOYSA-N 0.000 claims 1
- IMXGMEWHVAMODJ-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-methylsulfonylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 IMXGMEWHVAMODJ-UHFFFAOYSA-N 0.000 claims 1
- XQSDOJBTJZBNEB-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-nitrophenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C([N+]([O-])=O)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 XQSDOJBTJZBNEB-UHFFFAOYSA-N 0.000 claims 1
- CKAIKGOCBIYBCC-UHFFFAOYSA-N N-[5-tert-butyl-2-(4-sulfamoylphenyl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(S(N)(=O)=O)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 CKAIKGOCBIYBCC-UHFFFAOYSA-N 0.000 claims 1
- VFJOVTHKLWNEAT-UHFFFAOYSA-N N-[5-tert-butyl-2-(6-chloropyridazin-3-yl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(Cl)N=NC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 VFJOVTHKLWNEAT-UHFFFAOYSA-N 0.000 claims 1
- HXLFTRKRDXWTQY-UHFFFAOYSA-N N-[5-tert-butyl-2-(6-methylpyridin-3-yl)pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=NC(C)=CC=C1N1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 HXLFTRKRDXWTQY-UHFFFAOYSA-N 0.000 claims 1
- OCJHBHZRYZIRKZ-UHFFFAOYSA-N N-[5-tert-butyl-2-(diethylamino)-3-(methanesulfonamido)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(N(CC)CC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 OCJHBHZRYZIRKZ-UHFFFAOYSA-N 0.000 claims 1
- PKZDBHMGJKXJRM-UHFFFAOYSA-N N-[5-tert-butyl-2-(morpholine-4-carbonyl)thiophen-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1COCCN1C(=O)C=1SC(C(C)(C)C)=CC=1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 PKZDBHMGJKXJRM-UHFFFAOYSA-N 0.000 claims 1
- HFLUCDPQUAEACH-UHFFFAOYSA-N N-[5-tert-butyl-2-[3-(carbamoylamino)phenyl]pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(NC(N)=O)=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 HFLUCDPQUAEACH-UHFFFAOYSA-N 0.000 claims 1
- NIYVAPRPWZJTIL-UHFFFAOYSA-N N-[5-tert-butyl-2-[3-(trifluoromethyl)benzoyl]pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=O)N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 NIYVAPRPWZJTIL-UHFFFAOYSA-N 0.000 claims 1
- XOKGFSVQBOOJEN-UHFFFAOYSA-N N-[5-tert-butyl-2-[4-(carbamoylamino)phenyl]pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(NC(N)=O)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 XOKGFSVQBOOJEN-UHFFFAOYSA-N 0.000 claims 1
- WHDPRYKCFNISOU-UHFFFAOYSA-N N-[5-tert-butyl-2-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 WHDPRYKCFNISOU-UHFFFAOYSA-N 0.000 claims 1
- SHDOEFWHXQMGRL-UHFFFAOYSA-N N-[5-tert-butyl-2-ethoxy-3-(methanesulfonamido)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OCC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 SHDOEFWHXQMGRL-UHFFFAOYSA-N 0.000 claims 1
- ZSAWPPUKGUDLHI-UHFFFAOYSA-N N-[5-tert-butyl-2-hydroxy-3-(morpholin-4-ylmethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound OC=1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=CC=1CN1CCOCC1 ZSAWPPUKGUDLHI-UHFFFAOYSA-N 0.000 claims 1
- PUDCQZDFNYFQNJ-UHFFFAOYSA-N N-[5-tert-butyl-2-hydroxy-3-(piperidin-1-ylmethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound OC=1C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=CC=1CN1CCCCC1 PUDCQZDFNYFQNJ-UHFFFAOYSA-N 0.000 claims 1
- KMJOCMLVKKSYNH-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(2,2,2-trifluoroethylsulfonylamino)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(=O)(=O)CC(F)(F)F)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 KMJOCMLVKKSYNH-UHFFFAOYSA-N 0.000 claims 1
- CTDPKECAWWNOJF-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(3-oxopiperazine-1-carbonyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)N2CC(=O)NCC2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 CTDPKECAWWNOJF-UHFFFAOYSA-N 0.000 claims 1
- DPDSBDPSDYYSLY-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(morpholine-4-carbonyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)N2CCOCC2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 DPDSBDPSDYYSLY-UHFFFAOYSA-N 0.000 claims 1
- APPPYTFWOOONBT-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(piperidin-1-ylmethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)C(OC)=C1CN1CCCCC1 APPPYTFWOOONBT-UHFFFAOYSA-N 0.000 claims 1
- DKGHIJQVPQVQIR-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(piperidine-1-carbonyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)N2CCCCC2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 DKGHIJQVPQVQIR-UHFFFAOYSA-N 0.000 claims 1
- GNJRIROASRRSBG-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(propan-2-ylcarbamoylamino)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(NC(=O)NC(C)C)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 GNJRIROASRRSBG-UHFFFAOYSA-N 0.000 claims 1
- CSPHNVFUBYJQBX-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(propylsulfonylamino)phenyl]-2-(4-methoxynaphthalen-1-yl)-2-oxoacetamide Chemical compound CCCS(=O)(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OC)=CC=2)=C1OC CSPHNVFUBYJQBX-UHFFFAOYSA-N 0.000 claims 1
- FNRYKRVTECSVKK-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(propylsulfonylamino)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CCCS(=O)(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC FNRYKRVTECSVKK-UHFFFAOYSA-N 0.000 claims 1
- DIFCLHZHAFXKEB-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(propylsulfonylamino)phenyl]-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]-2-oxoacetamide Chemical compound CCCS(=O)(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OC=3N=C(N=CC=3)N3CCOCC3)=CC=2)=C1OC DIFCLHZHAFXKEB-UHFFFAOYSA-N 0.000 claims 1
- QCJNHASWXMRIFJ-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(propylsulfonylamino)phenyl]-2-[4-[(2-morpholin-4-ylpyridin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CCCS(=O)(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3C=C(N=CC=3)N3CCOCC3)=CC=2)=C1OC QCJNHASWXMRIFJ-UHFFFAOYSA-N 0.000 claims 1
- QMCOFSTZMMGTKG-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(propylsulfonylamino)phenyl]-2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CCCS(=O)(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3N=C(N=CC=3)N3CCOCC3)=CC=2)=C1OC QMCOFSTZMMGTKG-UHFFFAOYSA-N 0.000 claims 1
- JDFRPEFIPMFGNW-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(propylsulfonylamino)phenyl]-2-[4-[[2-(dimethylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CCCS(=O)(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(NC=3N=C(N=CC=3)N(C)C)=CC=2)=C1OC JDFRPEFIPMFGNW-UHFFFAOYSA-N 0.000 claims 1
- RMKMPDIYPIBFHJ-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-(trifluoromethyl)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(C(F)(F)F)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 RMKMPDIYPIBFHJ-UHFFFAOYSA-N 0.000 claims 1
- HPUDTMLIAVIJNH-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-[(2-methoxyacetyl)amino]phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COCC(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC HPUDTMLIAVIJNH-UHFFFAOYSA-N 0.000 claims 1
- HYVIXCYFEVZKFI-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-[(2-phenylacetyl)amino]phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)C(OC)=C1NC(=O)CC1=CC=CC=C1 HYVIXCYFEVZKFI-UHFFFAOYSA-N 0.000 claims 1
- UZGIERBLVWIXCP-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]phenyl]-2-methylpropanamide Chemical compound COC1=C(NC(=O)C(C)C)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 UZGIERBLVWIXCP-UHFFFAOYSA-N 0.000 claims 1
- PWBSIKFKPQBYLW-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]phenyl]benzamide Chemical compound C1=C(C(C)(C)C)C=C(NC(=O)C=2C=CC=CC=2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 PWBSIKFKPQBYLW-UHFFFAOYSA-N 0.000 claims 1
- UDZDWDQQUQUWME-UHFFFAOYSA-N N-[5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]phenyl]pyrrolidine-1-carboxamide Chemical compound C1=C(C(C)(C)C)C=C(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)C(OC)=C1NC(=O)N1CCCC1 UDZDWDQQUQUWME-UHFFFAOYSA-N 0.000 claims 1
- DBCUAWINNGVGBA-UHFFFAOYSA-N N-[5-tert-butyl-3-(diethylaminomethyl)-2-hydroxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CCN(CC)CC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1O DBCUAWINNGVGBA-UHFFFAOYSA-N 0.000 claims 1
- FKOFMGUSPWXXRE-UHFFFAOYSA-N N-[5-tert-butyl-3-(diethylcarbamoylamino)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CCN(CC)C(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC FKOFMGUSPWXXRE-UHFFFAOYSA-N 0.000 claims 1
- NERXFJOSINPKTF-UHFFFAOYSA-N N-[5-tert-butyl-3-(dimethylcarbamoylamino)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(NC(=O)N(C)C)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 NERXFJOSINPKTF-UHFFFAOYSA-N 0.000 claims 1
- FBESVIHALYOKMN-UHFFFAOYSA-N N-[5-tert-butyl-3-(ethylsulfonylamino)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound CCS(=O)(=O)NC1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC FBESVIHALYOKMN-UHFFFAOYSA-N 0.000 claims 1
- OINNPLJZUXRDGP-UHFFFAOYSA-N N-[5-tert-butyl-3-(imidazole-1-carbonyl)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(C(=O)N2C=NC=C2)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 OINNPLJZUXRDGP-UHFFFAOYSA-N 0.000 claims 1
- NXZBMERBUYMBAP-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-(1-methylindol-3-yl)-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C1=CN(C)C2=CC=CC=C12 NXZBMERBUYMBAP-UHFFFAOYSA-N 0.000 claims 1
- KRTJXGCIBLINBX-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-(1H-indol-3-yl)-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C1=CNC2=CC=CC=C12 KRTJXGCIBLINBX-UHFFFAOYSA-N 0.000 claims 1
- VPGRAFNAIUQWPV-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-(4-methoxynaphthalen-1-yl)-2-oxoacetamide Chemical compound C12=CC=CC=C2C(OC)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=CC(NS(C)(=O)=O)=C1OC VPGRAFNAIUQWPV-UHFFFAOYSA-N 0.000 claims 1
- GHVJWPAPNOOVKX-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-chloroethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C1=CC=C(OCCCl)C2=CC=CC=C12 GHVJWPAPNOOVKX-UHFFFAOYSA-N 0.000 claims 1
- ZWWULFVLBGOXGV-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-imidazol-1-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1C=NC=C1 ZWWULFVLBGOXGV-UHFFFAOYSA-N 0.000 claims 1
- IHCCPZUIAUOODE-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)-5,6,7,8-tetrahydronaphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C=1CCCCC=11)=CC=C1OCCN1CCOCC1 IHCCPZUIAUOODE-UHFFFAOYSA-N 0.000 claims 1
- UUROSJLZNDSXRF-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 UUROSJLZNDSXRF-UHFFFAOYSA-N 0.000 claims 1
- FQTSKVOXXUUFEJ-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylpyrimidin-4-yl)oxynaphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OC1=CC=NC(N2CCOCC2)=N1 FQTSKVOXXUUFEJ-UHFFFAOYSA-N 0.000 claims 1
- FEORRQJKXUYJEF-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(6-morpholin-4-ylpyridin-3-yl)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1C1=CC=C(N2CCOCC2)N=C1 FEORRQJKXUYJEF-UHFFFAOYSA-N 0.000 claims 1
- OYGDFBCGSIUKFB-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[(2-morpholin-4-ylpyridin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N2CCOCC2)=C1 OYGDFBCGSIUKFB-UHFFFAOYSA-N 0.000 claims 1
- BTEMDMBVMXBEKK-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[(2-morpholin-4-ylpyrimidin-4-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N2CCOCC2)=N1 BTEMDMBVMXBEKK-UHFFFAOYSA-N 0.000 claims 1
- JWJZTQFCANVDEL-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[(4-morpholin-4-ylpyrimidin-2-yl)amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=NC=CC(N2CCOCC2)=N1 JWJZTQFCANVDEL-UHFFFAOYSA-N 0.000 claims 1
- DHVHHWSVISPNMU-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[2-(1,4-oxazepan-4-yl)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCCC1 DHVHHWSVISPNMU-UHFFFAOYSA-N 0.000 claims 1
- FWZXQFARQRXVNL-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[2-(2,6-dimethylmorpholin-4-yl)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CC(C)OC(C)C1 FWZXQFARQRXVNL-UHFFFAOYSA-N 0.000 claims 1
- HESPPVVTFADQCC-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[2-(4-methylpiperazin-1-yl)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCN(C)CC1 HESPPVVTFADQCC-UHFFFAOYSA-N 0.000 claims 1
- WKPWLZYVMIAZEG-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[2-(diethylamino)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C12=CC=CC=C2C(OCCN(CC)CC)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=CC(NS(C)(=O)=O)=C1OC WKPWLZYVMIAZEG-UHFFFAOYSA-N 0.000 claims 1
- CDSJYKCAKNCPKQ-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[2-(dimethylamino)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C1=CC=C(OCCN(C)C)C2=CC=CC=C12 CDSJYKCAKNCPKQ-UHFFFAOYSA-N 0.000 claims 1
- ZFOHLIXIWRTJOR-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[2-(ethylamino)ethoxy]naphthalen-1-yl]-2-oxoacetamide Chemical compound C12=CC=CC=C2C(OCCNCC)=CC=C1C(=O)C(=O)NC1=CC(C(C)(C)C)=CC(NS(C)(=O)=O)=C1OC ZFOHLIXIWRTJOR-UHFFFAOYSA-N 0.000 claims 1
- NRXFJKIPKAUYTA-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[6-(morpholin-4-ylmethyl)pyridin-3-yl]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1C(C=N1)=CC=C1CN1CCOCC1 NRXFJKIPKAUYTA-UHFFFAOYSA-N 0.000 claims 1
- WCVYSWIBQQTZOY-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[6-(oxan-4-ylamino)pyridin-3-yl]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1C(C=N1)=CC=C1NC1CCOCC1 WCVYSWIBQQTZOY-UHFFFAOYSA-N 0.000 claims 1
- CRNKNGKOWDYFHM-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[[2-(dimethylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1NC1=CC=NC(N(C)C)=N1 CRNKNGKOWDYFHM-UHFFFAOYSA-N 0.000 claims 1
- KEHWOBPPUFTWHJ-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[[2-(methylamino)pyrimidin-4-yl]amino]naphthalen-1-yl]-2-oxoacetamide Chemical compound CNC1=NC=CC(NC=2C3=CC=CC=C3C(C(=O)C(=O)NC=3C(=C(NS(C)(=O)=O)C=C(C=3)C(C)(C)C)OC)=CC=2)=N1 KEHWOBPPUFTWHJ-UHFFFAOYSA-N 0.000 claims 1
- BNPABIXPVMDUKW-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[7-chloro-4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC(Cl)=CC=C11)=CC=C1OCCN1CCOCC1 BNPABIXPVMDUKW-UHFFFAOYSA-N 0.000 claims 1
- JUSDTNAHICLPMI-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[7-fluoro-4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC(F)=CC=C11)=CC=C1OCCN1CCOCC1 JUSDTNAHICLPMI-UHFFFAOYSA-N 0.000 claims 1
- RUYTXOYLKUGQLK-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[8-chloro-4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=C(Cl)C=CC=C11)=CC=C1OCCN1CCOCC1 RUYTXOYLKUGQLK-UHFFFAOYSA-N 0.000 claims 1
- XMJMAVNKIJGCQV-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[8-fluoro-4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=C(F)C=CC=C11)=CC=C1OCCN1CCOCC1 XMJMAVNKIJGCQV-UHFFFAOYSA-N 0.000 claims 1
- HSKIXCAWWMJPCC-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-hydrazinylidene-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=NN)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 HSKIXCAWWMJPCC-UHFFFAOYSA-N 0.000 claims 1
- SISDMUAQPXJRRZ-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-oxo-2-(4-pyridin-3-ylnaphthalen-1-yl)acetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1C1=CC=CN=C1 SISDMUAQPXJRRZ-UHFFFAOYSA-N 0.000 claims 1
- ARDMZIRXBHZWNW-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-oxo-2-[4-(2-piperazin-1-ylethoxy)naphthalen-1-yl]acetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCNCC1 ARDMZIRXBHZWNW-UHFFFAOYSA-N 0.000 claims 1
- WVLPPNXSNMDYFF-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-oxo-2-[4-(2-piperidin-1-ylpyrimidin-4-yl)oxynaphthalen-1-yl]acetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OC1=CC=NC(N2CCCCC2)=N1 WVLPPNXSNMDYFF-UHFFFAOYSA-N 0.000 claims 1
- WUPYBGVNJZKRSC-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-oxo-2-[4-[2-(3-oxopiperazin-1-yl)ethoxy]naphthalen-1-yl]acetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CC(=O)NCC1 WUPYBGVNJZKRSC-UHFFFAOYSA-N 0.000 claims 1
- DAEDQVOPZXCWRX-UHFFFAOYSA-N N-[5-tert-butyl-3-(methanesulfonamido)-2-propan-2-yloxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound C1=C(C(C)(C)C)C=C(NS(C)(=O)=O)C(OC(C)C)=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 DAEDQVOPZXCWRX-UHFFFAOYSA-N 0.000 claims 1
- JSILCPPLHTUDPQ-UHFFFAOYSA-N N-[5-tert-butyl-3-[[2-(dimethylamino)acetyl]amino]-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide Chemical compound COC1=C(NC(=O)CN(C)C)C=C(C(C)(C)C)C=C1NC(=O)C(=O)C(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 JSILCPPLHTUDPQ-UHFFFAOYSA-N 0.000 claims 1
- 208000004127 Nonketotic Hyperglycinemia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 208000007610 Optic Atrophy, Hereditary, Leber Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000002865 Osteopetrosis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 206010038294 Reiter's syndrome Diseases 0.000 claims 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010039000 Rett's disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 208000001653 Sulfite oxidase deficiency Diseases 0.000 claims 1
- 101710040537 TNF Proteins 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 206010044126 Tourette's disease Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000002917 arthritic Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 125000003828 azulenyl group Chemical group 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 201000004569 blindness Diseases 0.000 claims 1
- 201000010816 bone resorption disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VVIMUDKYLDLAJU-UHFFFAOYSA-N ethyl 2-[5-tert-butyl-2-methoxy-N-methylsulfonyl-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]anilino]acetate Chemical compound CCOC(=O)CN(S(C)(=O)=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC VVIMUDKYLDLAJU-UHFFFAOYSA-N 0.000 claims 1
- OUNMOOQPBVSPFU-FDEZRRJOSA-N ethyl N-[(E)-[2-(5-tert-butyl-3-carbamoyl-2-methoxyanilino)-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoethylidene]amino]carbamate Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1C(=N/NC(=O)OCC)\C(=O)NC1=CC(C(C)(C)C)=CC(C(N)=O)=C1OC OUNMOOQPBVSPFU-FDEZRRJOSA-N 0.000 claims 1
- HKJXQIQJXGZVAZ-GKPLWNPISA-N ethyl N-[(E)-[2-[(5-tert-butyl-2-methylpyrazol-3-yl)amino]-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoethylidene]amino]carbamate Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1C(=N/NC(=O)OCC)\C(=O)NC1=CC(C(C)(C)C)=NN1C HKJXQIQJXGZVAZ-GKPLWNPISA-N 0.000 claims 1
- HCZRULBBXMAYLZ-KGHBKMJJSA-N ethyl N-[(E)-[2-[5-tert-butyl-3-(cyclopropylcarbamoyl)-2-methoxyanilino]-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoethylidene]amino]carbamate Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1C(=N/NC(=O)OCC)\C(=O)NC(C=1OC)=CC(C(C)(C)C)=CC=1C(=O)NC1CC1 HCZRULBBXMAYLZ-KGHBKMJJSA-N 0.000 claims 1
- QAXNNYZIYUNJPQ-BIXQXLNPSA-N ethyl N-[(E)-[2-[5-tert-butyl-3-(ethylcarbamoyl)-2-methoxyanilino]-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoethylidene]amino]carbamate Chemical compound CCNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=N\NC(=O)OCC)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC QAXNNYZIYUNJPQ-BIXQXLNPSA-N 0.000 claims 1
- MVRAUTPJEMMGDO-OZMGXUMRSA-N ethyl N-[(E)-[2-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyanilino]-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoethylidene]amino]carbamate Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1C(=N/NC(=O)OCC)\C(=O)NC1=CC(C(C)(C)C)=CC(NS(C)(=O)=O)=C1OC MVRAUTPJEMMGDO-OZMGXUMRSA-N 0.000 claims 1
- OUNMOOQPBVSPFU-DKJXEYTPSA-N ethyl N-[(Z)-[2-(5-tert-butyl-3-carbamoyl-2-methoxyanilino)-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoethylidene]amino]carbamate Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1C(=N/NC(=O)OCC)/C(=O)NC1=CC(C(C)(C)C)=CC(C(N)=O)=C1OC OUNMOOQPBVSPFU-DKJXEYTPSA-N 0.000 claims 1
- HKJXQIQJXGZVAZ-ZXPTYKNPSA-N ethyl N-[(Z)-[2-[(5-tert-butyl-2-methylpyrazol-3-yl)amino]-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoethylidene]amino]carbamate Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1C(=N/NC(=O)OCC)/C(=O)NC1=CC(C(C)(C)C)=NN1C HKJXQIQJXGZVAZ-ZXPTYKNPSA-N 0.000 claims 1
- QAXNNYZIYUNJPQ-ZREQDNEKSA-N ethyl N-[(Z)-[2-[5-tert-butyl-3-(ethylcarbamoyl)-2-methoxyanilino]-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoethylidene]amino]carbamate Chemical compound CCNC(=O)C1=CC(C(C)(C)C)=CC(NC(=O)C(=N/NC(=O)OCC)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1OC QAXNNYZIYUNJPQ-ZREQDNEKSA-N 0.000 claims 1
- 201000011205 glycine encephalopathy Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 230000003225 hyperhomocysteinemia Effects 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- OBTPMQFPBYQLFP-KRUMMXJUSA-N methyl 5-tert-butyl-3-[[(2Z)-2-hydroxyimino-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]acetyl]amino]thiophene-2-carboxylate Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=N/O)\C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1C(=O)OC OBTPMQFPBYQLFP-KRUMMXJUSA-N 0.000 claims 1
- CXDIDHCGZWQWKA-UHFFFAOYSA-N methyl 5-tert-butyl-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]thiophene-2-carboxylate Chemical compound S1C(C(C)(C)C)=CC(NC(=O)C(=O)C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=C1C(=O)OC CXDIDHCGZWQWKA-UHFFFAOYSA-N 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 201000001365 retinal ischemia Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 201000003176 severe acute respiratory syndrome Diseases 0.000 claims 1
- 201000010001 silicosis Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 201000010044 viral meningitis Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Claims (25)
- 式IA:
Xは,C(O)またはC(S)であり;
Gは,C3−10カルボシクリル,O,NまたはSから選択される1またはそれ以上の複素原子を含む5−8員の一環ヘテロシクリルまたは8−11員の二環ヘテロシクリルであり;ここで,Gは,1またはそれ以上のR1,R2またはR3で置換されており;
Arは,−(Y)−(C0−3アルキル)−(二環アリール),または−(Y)−(C0−3アルキル)−(二環ヘテロアリール)であり,ここで,二環ヘテロアリールは,インダゾリル,イソインドリル,キノリニル,イソキノリニル,フタラジニル,ジヒドロインドリル,ベンゾフラニル,ベンズオキサゾリル,ベンゾイソオキサゾリル,ジヒドロベンゾイソオキサゾリル,ジヒドロイソインドリル,ベンズイミダゾリル,ベンゾチエニル,ベンゾチアゾリル,ベンゾイソチアゾリル,またはベンゾイソチアゾリルジオキシドであり,およびArは,1またはそれ以上のR4またはR5で任意に置換されていてもよく;ただし,二環アリールは1,1,4,4−テトラメチル−1,2,3,4−テトラヒドロ−ナフチルではなく;
Yは,−C(O)−,−C(NNRC(O)OR)−,−C(NNRR)−,−C(NNC(O)NRR)または−C(NOR)−であり;
Lは,共有結合または飽和または不飽和の分枝鎖または非分枝鎖のC1−10炭素鎖であり,ここで,1またはそれ以上のメチレン基は,任意に独立して,O,NRおよびS(O)mから選択される複素原子で置き換えられていてもよく;および,Lは,0−2個のオキソ基および,1またはそれ以上のF,Cl,Br,またはIで任意に置換されていてもよい1またはそれ以上のC1−4の分枝鎖または非分枝鎖のアルキルで任意に置換されていてもよく;
各mは,独立して,0,1または2であり;
Qは,水素,−NR’R’,シクロアルキル,アリール,ヘテロシクリル,C1−6アルコキシ,C1−6アルキル−S(O)m,またはフェニル−S(O)mであり,ここで,シクロアルキル,アリール,ヘテロシクリル,C1−6アルコキシ,C1−6アルキル−S(O)m,またはフェニル−S(O)mは,それぞれ1またはそれ以上のR27で任意に置換されていてもよく;ただし,R4およびR5が存在しない場合,−L−Qは−Hではなく;
各Rは,独立して,水素または置換または未置換のC1−6アルキルであり;
各R’は,独立して,水素,置換または未置換のC1−8アルキル,置換または未置換の(C0−4アルキル)−(C6−10アリール)または置換または未置換の(C0−4アルキル)−(5−10員のヘテロシクリル)であり;
各R1は,独立して,F,Cl,Br,I,シアノ,−C(O)R,−C(O)NR2,−C(O)OR,−OR,−NR’R’,−SiR3,−S(O)mR,置換または未置換の直鎖または分枝鎖のC1−10アルキル,C2−10アルケニル,またはC2−10アルキニル,置換または未置換のC3−10シクロアルキル,置換または未置換のC5−8シクロアルケニル,置換または未置換のC7−20アラルキル,N,O,S(O)mから独立して選択される1,2,3,または4個の複素原子を含む置換または未置換の飽和または不飽和の3−11員のヘテロシクリルまたはヘテロシクリルアルキルであり;
各R2,R4およびR5は,独立して,F,Cl,Br,I,シアノ,置換または未置換の直鎖または分枝鎖のC1−6アルキル,置換または未置換のC6−10アリール,置換または未置換の5−10員のヘテロアリール,−OR’,−OR6,−C(O)R’,−C(O)OR’,−C(O)NR’2,−NR’2,−NO2,−S(O)mR",−NR’SO2R",−NR’C(O)NR’R’,−NR’C(S)NR’R’,−NR’C(O)OR’または−SO2NR’2であり;
各R"は,独立して,置換または未置換のC1−8アルキル,置換または未置換のC0−4アルキル−C6−10アリールまたは置換または未置換の(C0−4アルキル)−(5−10員のヘテロシクリル)であり;
各R3は,独立して,H,置換または未置換のC6−10アリール,N,O,S(O)mから独立して選択される1,2,3,または4個の複素原子を含む置換または未置換の飽和または不飽和の3−11員のヘテロシクリルまたはヘテロシクリルアルキル,置換または未置換のC3−12シクロアルキル,置換または未置換のC5−12シクロアルケニル,置換または未置換のC7−20アラルキル,置換または未置換の直鎖または分枝鎖のC1−8アルキル,R20C(O)N(R21)−,R22O−,R23R24NC(O)−,R26(CH2)mC(O)N(R21)−,R26C(O)(CH2)mN(R21)−,置換または未置換のC2−8アルケニル,または置換または未置換のC2−8アルキニルであり,ここで,C1−8アルキル,C2−8アルケニル,またはC2−8アルキニルの1またはそれ以上のメチレン基はO,NH,またはS(O)mで任意に置き換えられていてもよく;
各R6は,任意に部分的にまたは完全にハロゲン化されていてもよくR26で任意に置換されていてもよいC1−6の分枝鎖または非分枝鎖のアルキルであり;
各R26は,独立して,シアノ,モルホリノ,ピペリジニル,ピペラジニル,イミダゾリル,フェニル,ピリジニル,テトラゾリル,または任意に部分的にまたは完全にハロゲン化されていてもよいモノ−またはジ−(C0−4アルキル)アミノであり;
R20は,置換または未置換のC1−10アルキル,置換または未置換のC0−6アルキル−フェニル,置換または未置換のC0−6アルキル−ヘテロシクリル,OR’またはNR’2であり:
R21は,水素または任意に部分的にまたは完全にハロゲン化されていてもよいC1−4の分枝鎖または非分枝鎖のアルキルであり;および
各R22,R23およびR24は,独立して,水素,置換または未置換のC1−10アルキル(ここで,C1−10アルキルには,1またはそれ以上のO,NまたはSが任意に割り込んでいてもよい),置換または未置換のC0−6アルキル−フェニル,置換または未置換のC0−6アルキル−ヘテロシクリルであり;または,R23およびR24は,一緒になって複素環またはヘテロアリール環を形成してもよく;
各R27は,独立して,F,Cl,Br,I,シアノ,−C(O)R’,−C(O)NR’2,−C(O)OR’,−OR’,−NR’R’,−SiR’3,−S(O)mR’,置換または未置換の直鎖または分枝鎖のC1−10アルキル,C2−10アルケニル,またはC2−10アルキニル,置換または未置換のC3−10シクロアルキル,置換または未置換のC5−8シクロアルケニル,置換または未置換のC7−20アラルキル,N,O,S(O)mから独立して選択される1,2,3,または4個の複素原子を含む置換または未置換の3−11員のヘテロシクリルまたはヘテロシクリルアルキルであり;
ただし,Arが−(Y)−(二環アリール)であり,GがN−(置換または未置換のフェニル)−ピラゾリルであるとき,ピラゾリルは,さらに1またはそれ以上のR1,R2またはR3で置換されており;および
IAはN−(4−クロロ−3−メチル−イソチアゾール−5−イル)−2−[2−(2,2−ジメチル−プロピル)−ベンゾオキサゾール−5−イル]−2−オキソ−アセトアミドではない]
を有するサイトカイン阻害剤,その立体異性体,その互変異性体,その溶媒和物,そのプロドラッグ,および薬学的に許容しうる塩。 - 化合物が10μMの濃度で細胞からの誘導性TNFa−放出を約50%または50%より大きく阻害する,請求項1記載の化合物。
- Gは,フェニル,ナフチル,シクロプロピル,ピラゾリル,ピロリル,ピロリジニル,イミダゾリル,イミダゾロニル,チアゾリル,オキサゾリル,イソオキサゾリル,フラニル,チエニル,またはピリジニルである,請求項1記載の化合物。
- Arは,−(Y)−(C0−3アルキル)−(二環アリール)であり,および二環アリールは,ナフチル,テトラヒドロナフチル,ジヒドロナフチル,インデニル,インダニルまたはアズレニルである,請求項1記載の化合物。
- Yは,−C(O)−,−C(NNRC(O)OR)−または−C(NOR)−である,請求項4記載の化合物。
- Lは,共有結合,C1−C9アルコキシ,−C(O)O−,−NH−または−O−である,請求項1記載の化合物。
- Qは,モルホリノ,ピペラジニル,ピリミジニルまたはピリジニルである,請求項1記載の化合物。
- R27は,−C(O)OR,−NR’R’,置換または未置換の直鎖または分枝鎖のC1−10アルキル,置換または未置換のC7−20アラルキル,またはN,O,S(O)mから独立して選択される1,2,3,または4個の複素原子を含む置換または未置換の飽和または不飽和の3−11員のヘテロシクリルまたはヘテロシクリルアルキルである,請求項7記載の化合物。
- 各R1は,独立して,任意に部分的にまたは完全にハロゲン化されていてもよく1−3個のC3−10シクロアルキル,ヒドロキシフェニル,ナフチル,ピリジニル,ピリミジニル,ピラジニル,ピリダジニル,ピロリル,イミダゾリル,ピラゾリル,チエニル,フリル,イソオキサゾリル,またはイソチアゾリル(このそれぞれは,1−5個のハロゲンで任意に置換されていてもよい)で任意に置換されていてもよいC3−10の分枝鎖または非分枝鎖のアルキル,任意に部分的にまたは完全にハロゲン化されていてもよいC1−6分枝鎖または非分枝鎖のアルキル,C3−8シクロアルキル,C5−8シクロアルケニル,ヒドロキシ,シアノ,任意に部分的にまたは完全にハロゲン化されていてもよいC1−3アルコキシおよびNH2C(O)またはモノ−またはジ−(C1−3アルキル)アミノカルボニルである,請求項1記載の化合物。
- 各R2は,独立して,−NR’2,−NO2,−C(O)NR’2,−NR’SO2R",−NR’C(O)NR’R’,−NR’C(S)NR’R’,−NR’C(O)OR’または−SO2NR’2である,請求項1記載の化合物。
- 各R3は,独立して,
フェニル,ピリダジニルまたはピリジル,このそれぞれは,任意に部分的にまたは完全にハロゲン化されていてもよく,および任意に部分的にまたは完全にハロゲン化されていてもよいC1−6の分枝鎖または非分枝鎖のアルキル,ヒドロキシ,オキソ,シアノ,任意に部分的にまたは完全にハロゲン化されていてもよいC1−3アルコキシ,ニトロ,アミノ,またはモノ−またはジ−(C1−3アルキル)アミノで任意に置換されていてもよく;
C1−6アルキルまたはC1−6アルコキシ,このそれぞれは,任意に部分的にまたは完全にハロゲン化されていてもよく,またはR17,アミノ,OR18,R19で任意に置換されていてもよいC1−5モノ−またはジ−アルキルアミノで任意に置換されていてもよく;または
R20C(O)N(R21)−,R22O−,R23R24NC(O)−,R26(CH2)mC(O)N(R21)−またはR26C(O)(CH2)mN(R21)−
である,請求項1記載の化合物。 - XがC=Oである,請求項1記載の化合物。
- Arは−(Y)−ナフチル−であり,Yは,−C(O)−,または−C(=NOH)−であり,およびGは,フェニル,ピリジニル,ピラゾリル,ピロリル,イミダゾリル,オキサゾリル,イソオキサゾリル,フラニルまたはチエニルである,請求項1記載の化合物。
- Arは−(Y)−ナフチル−であり,Yは,−C(O)−,または−C(=NOH)−であり,およびGは,フェニルまたはピリジルである,請求項1記載の化合物。
- 各R1は,独立して,置換または未置換の直鎖または分枝鎖のC1−10アルキルである,請求項14記載の化合物。
- 各R3は,独立して,R23R24N−C(O)−,R20−C(O)−NR21−,またはOR22である,請求項15記載の化合物。
- 各R2は,独立して,−NR’SO2R",−Cl,−Br,−F,−C(O)−NR’2,置換または未置換の直鎖または分枝鎖のC1−6アルキル,−NR’2,または−OR’である,請求項16記載の化合物。
- Arは−(Y)−ナフチル−であり,Yは,−C(O)−,または−C(=NOH)−であり,およびGは,ピラゾリル,チエニルまたはイソオキサゾリルである,請求項1記載の化合物。
- 各R1は,独立して,置換または未置換の直鎖または分枝鎖のC1−10アルキルである,請求項18記載の化合物。
- 各R3は,独立して,1,2,または3個の−F,−Clで任意に置換されていてもよい,置換または未置換のC1−6分枝鎖または非分枝鎖のアルキルまたは置換または未置換のC1−4アルコキシフェニルまたはピリジニルである,請求項19記載の化合物。
- サイトカインにより媒介される疾病を治療するための医薬組成物であって,治療上有効量の請求項1記載の化合物および薬学的に許容しうる担体を含む医薬組成物。
- サイトカイン−媒介性疾病が,慢性関節リウマチ,変形性関節症,クローン病,潰瘍性大腸炎,乾癬性関節炎,外傷性関節炎,風疹性関節炎,炎症性大腸疾患,多発性硬化症,移植片対宿主病,全身性エリテマトーデス,中毒性ショック症候群,過敏性腸管症候群,筋肉変性,同種移植拒絶,膵炎,インスリン炎,糸球体腎炎,糖尿病性腎症,腎線維症,痛風,らい,急性滑膜炎,ライター症候群,通風性関節炎,ベーチェット病,脊椎炎,子宮内膜症,非関節性炎症性状態,急性または慢性の痛み,発作,慢性心不全,内毒素血症;再潅流傷害,虚血性再潅流,心筋虚血,再狭窄,血栓症,血管新生,冠状動脈心臓疾病,冠状動脈疾病,急性冠状動脈症候群,心臓性不全,高コレステロール血症,血液凝固またはフィブリン溶解に関連する疾病または状態,アテローム性動脈硬化症,アレルギー性結膜炎,ブドウ膜炎,緑内障,視神経炎,網膜虚血,糖尿病性網膜症,レーザー誘導性視障害,外科手術または外傷誘導性増殖性硝子体網膜症,アレルギー性鼻炎,喘息,成人呼吸窮迫症候群,慢性肺炎,慢性閉塞性肺疾病,気腫,気管支炎,粘液分泌過多,珪肺症,SARS感染,呼吸管炎症,乾癬,アトピー性皮膚炎,接触皮膚炎,アクネ,ギヤン・バレー症候群,パーキンソン病,ハンチントン病,アルツハイマー病,筋萎縮性側索硬化症,多発性硬化症および他の脱髄疾患,ウイルス性および細菌性髄膜炎,CNS外傷,脊髄傷害,癲癇発作,痙攣,オリーブ橋小脳萎縮,AIDSエイズ痴呆群,MERRFおよびMELAS症候群,レーバー病,ウェミック脳症,レット症候群,ホモシステイン尿症,高プロリン血症,高ホモシステイン血症,非ケトン性高グリシン血症,ヒドロキシ酪酸アミン酸尿症,亜硫酸オキシダーゼ欠損症,脊髄索状変性,鉛脳障害,トゥレット症候群,肝性脳障害,薬剤嗜癖,薬剤耐性,薬物依存,うつ病,不安および精神分裂病,動脈瘤,てんかん,糖尿病,全身性悪液質,感染または悪性により続発する悪液質,後天性免疫不全症候群により続発する悪液質,肥満症,食欲不振および神経性大食症,骨再吸収疾病,大理石骨病,骨粗鬆症,敗血症,HIV,マラリア,感染性関節炎,リーシュマニア症,ライム病,癌,キャッスルマン病,幹細胞治療標的,または薬剤耐性である,請求項21記載の医薬組成物。
- サイトカイン媒介性疾病が,慢性関節リウマチ,変形性関節症,クローン病,潰瘍性大腸炎,乾癬性関節炎,外傷性関節炎,風疹性関節炎,炎症性大腸疾患,多発性硬化症,乾癬,移植片対宿主病,全身性エリテマトーデス,中毒性ショック症候群,過敏性腸管症候群,筋肉変性,同種移植拒絶,膵炎,インスリン炎,糸球体腎炎,糖尿病性腎症,腎線維症,痛風,急性滑膜炎,ライター症候群,通風性関節炎,ベーチェット病,脊椎炎,子宮内膜症,非関節性炎症性状態,急性または慢性の痛みである,請求項22記載の医薬組成物。
- サイトカイン媒介性疾病が,発作,慢性心不全,内毒素血症;再潅流傷害,虚血性再潅流,心筋虚血,再狭窄,血栓症,血管新生,冠状動脈心臓疾病,冠状動脈疾病,急性冠状動脈症候群,心臓性不全,高コレステロール血症,血液凝固またはフィブリン溶解に関連する疾病または状態,またはアテローム性動脈硬化症である,請求項22記載の医薬組成物。
- N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−ヒドロキシ−3−モルホリン−4−イルメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−ヒドロキシ−3−メチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−3−メチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−クロロ−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−3−トリフルオロメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[7−クロロ−4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N−シクロプロピル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−[5−tert−ブチル−2−メトキシ−3−(ピペリジン−1−カルボニル)−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−2−ヒドロキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−安息香酸;
N−(2−ベンゼンスルホニル−5−tert−ブチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[(Z)−メトキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−オキソ−2−[4−(2−ピペリジン−1−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−アセトアミド;
N−[5−tert−ブチル−2−(2,5−ジフルオロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−(4−メトキシ−ナフタレン−1−イル)−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3−クロロ−ベンゾイル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3−メタンスルホニル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[3−(ベンゼンスルホニル−カルバモイルメチル−アミノ)−5−tert−ブチル−2−メトキシ−フェニル]−2−ナフタレン−1−イル−2−オキソ−アセトアミド;
N−(3−tert−ブチル−イソオキサゾール−5−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(4−スルファモイル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
2−(4−ブロモ−ナフタレン−1−イル)−N−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イル)−2−オキソ−アセトアミド;
5−tert−ブチル−2−ヒドロキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(6−モルホリン−4−イルメチル−ピリジン−3−イル)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−メチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−ジメチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−2−{4−[2−(1−オキソ−1λ4−チオモルホリン−4−イル)−エトキシ]−ナフタレン−1−イル}−アセトアミド;
5−tert−ブチル−3−{2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセチルアミノ}−チオフェン−2−カルボン酸メチルエステル;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−{4−[2−((2R,6R)−2,6−ジメチル−モルホリン−4−イル)−エトキシ]−ナフタレン−1−イル}−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イル)−2−[4−(6−モルホリン−4−イルメチル−ピリジン−3−イル)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[7−クロロ−4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(6−モルホリン−4−イルメチル−ピリジン−3−イル)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N−シクロプロピル−2−メトキシ−3−[2−(4−メトキシ−ナフタレン−1−イル)−2−オキソ−アセチルアミノ]−ベンズアミド;
N−(2−アセチル−5−tert−ブチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N−シクロプロピル−3−{2−ヒドラゾノ−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセチルアミノ}−2−メトキシ−ベンズアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−ヒドラゾノ−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(3,4−ジメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−シクロヘキシル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−オキソ−2−(4−ピリジン−3−イル−ナフタレン−1−イル)−アセトアミド;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−ジエチルアミノ−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−2−{4−[2−(3−オキソ−[1,4]ジアゼピン−1−イル)−エチル]−ナフタレン−1−イル}−アセトアミド;
5−tert−ブチル−N−エチル−2−メトキシ−3−[2−(4−メトキシ−ナフタレン−1−イル)−2−オキソ−アセチルアミノ]−ベンズアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−オキソ−2−{4−[6−(テトラヒドロ−ピラン−4−イルアミノ)−ピリジン−3−イル]−ナフタレン−1−イル}−アセトアミド;
N−(2,5−ジメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
ピロリジン−1−カルボン酸(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−アミド;
N−(3−アミノ−5−tert−ブチル−2−メトキシ−フェニル)−2−オキソ−2−{4−[2−((S)−1−フェニル−エチルアミノ)−ピリミジン−4−イルアミノ]−ナフタレン−1−イル}−アセトアミド;
5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−ベンズアミド;
N−(3,5−ジ−tert−ブチル−2−メトキシ−フェニル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N’−[1−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(E)−イリデン]−ヒドラジンカルボキサミド;
5−tert−ブチル−3−{2−[(Z)−メトキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセチルアミノ}−チオフェン−2−カルボン酸アミド;
5−tert−ブチル−N−シクロプロピルメチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−[5−tert−ブチル−2−メトキシ−3−(2−メトキシ−アセチルアミノ)−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−イソプロポキシ−3−メタンスルホニルアミノ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3,4−ジメチル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−2−[4−(2−チオモルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−ジメチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
1−(2−アミノ−4−tert−ブチル−6−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−ピリジニウム;
N−(5−tert−ブチル−2−イソプロポキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−m−トリル−2H−ピラゾール−3−イル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
5−tert−ブチル−2−メトキシ−3−[2−(4−メトキシ−ナフタレン−1−イル)−2−オキソ−アセチルアミノ]−ベンズアミド;
5−tert−ブチル−2−メトキシ−N−(2−メトキシ−エチル)−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−カルバミン酸メチルエステル;
3−tert−ブチル−5−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ピラゾール−1−カルボン酸アダマンタン−1−イルアミド;
5−tert−ブチル−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−チオフェン−2−カルボン酸アミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−{4−[2−(2,6−ジメチル−モルホリン−4−イル)−エチル]−ナフタレン−1−イル}−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
3−tert−ブチル−5−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ピラゾール−1−カルボン酸tert−ブチルアミド;
3−tert−ブチル−5−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ピラゾール−1−カルボン酸アミド;
N−アリル−5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−[(Z)−メトキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(3−アセチルアミノ−5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−アセチルアミノ}−チオフェン−2−カルボン酸アミド;
N−[3−(4−アセチル−ピペラジン−1−カルボニル)−5−tert−ブチル−2−メトキシ−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−4−メチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−N−(2−フェニル−シクロプロピル)−アセトアミド;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−[4−(6−モルホリン−4−イルメチル−ピリジン−3−イル)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2,3−ジメトキシ−フェニル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−{4−[2−(4−メチル−ピペラジン−1−イル)−エチル]−ナフタレン−1−イル}−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−(1H−インドール−3−イル)−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−ピリジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(4−tert−ブチル−6−トリフルオロメチル−ピリミジン−2−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセチルアミノ}−チオフェン−2−カルボン酸メチルアミド;
N−[5−tert−ブチル−2−(3,5−ジクロロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−{4−[2−((2R,6S)−2,6−ジメチル−モルホリン−4−イル)−エトキシ]−ナフタレン−1−イル}−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[4−(2−イミダゾール−1−イル−エチル)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−3−フェニルメタンスルホニルアミノ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−2−[4−(2−ピリジン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−[5−tert−ブチル−2−(3−クロロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(6−クロロ−ピリダジン−3−イル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−m−トリル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N−シクロプロピル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
[(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−メタンスルホニル−アミノ]−酢酸エチルエステル;
N−(5−tert−ブチル−4−メチル−2−m−トリル−2H−ピラゾール−3−イル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−[5−tert−ブチル−2−(2,5−ジクロロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[4−(2−[1,4]オキサゼパン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(2−ブロモ−5−トリフルオロメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N−シクロペンチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−[5−tert−ブチル−2−(モルホリン−4−カルボニル)−チオフェン−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N−シクロプロピルメチル−2−メトキシ−3−[2−(4−メトキシ−ナフタレン−1−イル)−2−オキソ−アセチルアミノ]−ベンズアミド;
N−[5−tert−ブチル−3−(3,3−ジエチル−ウレイド)−2−メトキシ−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(4−フルオロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(2−ベンジル−5−tert−ブチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−オキソ−2−[4−(2−ピペラジン−1−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−ピリジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−カルバミン酸イソプロピルエステル;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[3−(3−アリル−ウレイド)−5−tert−ブチル−2−メトキシ−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N,N−ジエチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−[1,4]オキサゼパン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(3−tert−ブチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(6−メチル−ピリジン−3−イル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(4−ウレイド−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−m−トリル−2H−ピラゾール−3−イル)−2−[4−(2−ジメチルアミノ−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−オキソ−2−[4−(2−ピペリジン−1−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−アセトアミド;
N−[5−tert−ブチル−2−(3−フルオロ−4−メチル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[3,5−ビス−(1,1−ジメチル−プロピル)−2−メトキシ−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
4−{2−[4−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニルアミノオキサリル)−ナフタレン−1−イルオキシ]−エチル}−ピペラジン−1−カルボン酸エチルエステル;
N−(3−アミノ−5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−3−(2−ジメチルアミノ−アセチルアミノ)−2−メトキシ−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−ジメチルアミノ−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−[1,3,4]チアジアゾール−2−イル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−2−エトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−カルバミン酸2−メトキシ−エチルエステル;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[4−(2−イミダゾール−1−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(4−ブロモ−3−トリフルオロメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[8−クロロ−4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−クロロ−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−チオフェン−2−カルボン酸ジメチルアミド;
N−(4−クロロ−3−トリフルオロメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N’−[1−(5−tert−ブチル−3−エチルカルバモイル−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(Z)−イリデン]−ヒドラジンカルボン酸エチルエステル;
N−[5−tert−ブチル−2−(3−クロロ−ベンゼンスルホニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−ジエチルアミノ−3−メタンスルホニルアミノ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−メトキシ−3−(プロパン−1−スルホニルアミノ)−フェニル]−2−(4−メトキシ−ナフタレン−1−イル)−2−オキソ−アセトアミド;
2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−N−(3−トリフルオロメチル−フェニル)−アセトアミド;
N−[5−tert−ブチル−2−(4−トリフルオロメチル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−メトキシ−3−(プロパン−1−スルホニルアミノ)−フェニル]−2−[4−(2−ジメチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−メトキシ−3−(プロパン−1−スルホニルアミノ)−フェニル]−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−{4−[2−(2,6−ジメチル−モルホリン−4−イル)−エトキシ]−ナフタレン−1−イル}−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−2−{4−[2−(3−オキソ−ピペラジン−1−イル)−エチル]−ナフタレン−1−イル}−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−2−[4−(3−ピリジン−4−イル−プロポキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−5,6,7,8−テトラヒドロ−ナフタレン−1−イル]−アセトアミド;
N−[5−tert−ブチル−2−(4−メタンスルホニル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−イミダゾール−1−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3,5−ジメチル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−ピリジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−{5−tert−ブチル−3−[カルバモイルメチル−(プロパン−1−スルホニル)−アミノ]−2−メトキシ−フェニル}−2−ナフタレン−1−イル−2−オキソ−アセトアミド;
N’−[1−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(Z)−イリデン]−ヒドラジンカルボン酸エチルエステル;
N−[5−tert−ブチル−2−(3−ニトロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[3−クロロ−4−(2−モルホリン−4−イル−エトキシ)−フェニル]−2−オキソ−アセトアミド;
N−(3−ベンゼンスルホニルアミノ−5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
3−tert−ブチル−5−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ピラゾール−1−カルボン酸シクロヘキシルアミド;
N−[5−tert−ブチル−2−メトキシ−3−(2,2,2−トリフルオロ−エタンスルホニルアミノ)−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N’−[1−(5−tert−ブチル−3−カルバモイル−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(E)−イリデン]−ヒドラジンカルボン酸エチルエステル;
(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−カルバミン酸2−ジメチルアミノ−エチルエステル;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[7−フルオロ−4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−[4−(2−モルホリン−4−イル−ピリジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イル)−2−(4−メトキシ−ナフタレン−1−イル)−2−オキソ−アセトアミド;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−(4−メトキシ−ナフタレン−1−イル)−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3−メトキシ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−ジメチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(2−クロロ−5−トリフルオロメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(3−メタンスルホニルアミノ−2−メトキシ−5−メチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
4−{2−[4−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イルアミノオキサリル)−ナフタレン−1−イル]−エチル}−ピペラジン−1−カルボン酸エチルエステル;
N−(3,5−ジ−tert−ブチル−2−ヒドロキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−ナフタレン−1−イル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
4−{2−[4−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イルアミノオキサリル)−ナフタレン−1−イルオキシ]−エチル}−ピペラジン−1−カルボン酸エチルエステル;
5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−(1−メチル−1H−インドール−3−イル)−2−オキソ−アセトアミド;
N−[2−(4−アセチル−フェニル)−5−tert−ブチル−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−3−(カルバモイルメチル−メタンスルホニル−アミノ)−2−メトキシ−フェニル]−2−ナフタレン−1−イル−2−オキソ−アセトアミド;
N−[2−(4−アミノ−フェニル)−5−tert−ブチル−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−カルバミン酸フェニルエステル;
N−(5−tert−ブチル−2−イソブトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(4−tert−ブチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3−メチル−ベンゾイル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセチルアミノ}−チオフェン−2−カルボン酸アミド;
N−[5−tert−ブチル−2−(2,3−ジメチル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(4−ニトロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
2−[(Z)−ヒドロキシイミノ]−N−(3−メタンスルホニルアミノ−2−メトキシ−5−メチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−[5−tert−ブチル−2−(モルホリン−4−カルボニル)−チオフェン−3−イル]−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−tert−ブチル−2−フェニル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N’−[1−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(E)−イリデン]−ヒドラジンカルボン酸エチルエステル;
N’−[1−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(Z)−イリデン]−ヒドラジンカルボキサミド;
N−[5−tert−ブチル−2−(3−メトキシ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−N−ピリジン−2−イル−ベンズアミド;
N−[5−tert−ブチル−3−(3,3−ジメチル−ウレイド)−2−メトキシ−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[7−クロロ−4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−2−メトキシ−ベンズアミド;
2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−N−キノリン−3−イル−アセトアミド;
N−[5−tert−ブチル−2−メトキシ−3−(モルホリン−4−カルボニル)−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−3−(3−イソプロピル−ウレイド)−2−メトキシ−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(3−アミノ−5−トリフルオロメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
2−{4−[2−(4−アセチル−ピペラジン−1−イル)−エトキシ]−ナフタレン−1−イル}−N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3−フルオロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3,4−ジクロロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(2,5−ジメチル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−5,6,7,8−テトラヒドロ−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(4−クロロ−3−トリフルオロメチル−フェニル)−2−(4−メトキシ−ナフタレン−1−イル)−2−オキソ−アセトアミド;
N−[5−(1,1−ジメチル−ブチル)−2−p−トリル−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N’−[1−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(E)−イリデン]−ヒドラジンカルボキサミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−メチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−m−トリル−2H−ピラゾール−3−イル)−2−[(Z)−メトキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
5−tert−ブチル−N−シクロプロピル−3−[2−[(E)−ヒドロキシイミノ]−2−(4−メトキシ−ナフタレン−1−イル)−アセチルアミノ]−2−メトキシ−ベンズアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−{4−[2−(2,6−ジメチル−モルホリン−4−イル)−エトキシ]−ナフタレン−1−イル}−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[8−フルオロ−4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N−フラン−2−イルメチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−[5−tert−ブチル−2−(3−トリフルオロメチル−ベンゾイル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−メトキシ−3−(プロパン−1−スルホニルアミノ)−フェニル]−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−オキソ−2−{4−[2−(3−オキソ−ピペラジン−1−イル)−エトキシ]−ナフタレン−1−イル}−アセトアミド;
2−{4−[2−(4−アセチル−ピペラジン−1−イル)−エチル]−ナフタレン−1−イル}−N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−フェニルアセチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−2−{4−[2−(3−オキソ−ピペラジン−1−イル)−エトキシ]−ナフタレン−1−イル}−アセトアミド;
N−[5−tert−ブチル−2−(3−ウレイド−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[(Z)−メトキシイミノ]−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−アセトアミド;
N−[5−tert−ブチル−2−メトキシ−3−(3−オキソ−ピペラジン−1−カルボニル)−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
3−tert−ブチル−5−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ピラゾール−1−カルボン酸プロピルアミド;
5−tert−ブチル−N−シクロプロピル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−{4−[2−(4−メチル−ピペラジン−1−イル)−エトキシ]−ナフタレン−1−イル}−2−オキソ−アセトアミド;
N−(3−アミノ−5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−N−プロピル−ベンズアミド;
N−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(5−イソプロピル−2−メチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−カルバミン酸ピリジン−3−イルメチルエステル;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−エチルアミノ−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(3,5−ジ−tert−ブチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(3−アミノ−5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−メチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(2,3−ジクロロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[3,5−ビス−(1,1−ジメチル−プロピル)−2−ヒドロキシ−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
4−{2−[4−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニルアミノオキサリル)−ナフタレン−1−イルオキシ]−エチル}−ピペラジン−1−カルボン酸tert−ブチルエステル;
5−tert−ブチル−N−イソプロピル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−3−ジエチルアミノメチル−2−ヒドロキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−m−トリル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(4−モルホリン−4−イル−ピリミジン−2−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(3−アミノ−5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−チオフェン−2−カルボン酸メチルアミド;
N−[5−tert−ブチル−2−(3−メトキシ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N’−[1−(5−tert−ブチル−3−カルバモイル−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(Z)−イリデン]−ヒドラジンカルボン酸エチルエステル;
N−(4−フルオロ−3−トリフルオロメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(2,5−ジ−tert−ブチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−N−((1S,2R)−2−フェニル−シクロプロピル)−アセトアミド;
N−(2−メトキシ−5−トリフルオロメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[2−(4−ブロモ−フェニル)−5−tert−ブチル−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−2−メトキシ−N−メチル−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−2−メトキシ−3−ピペリジン−1−イルメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−ナフタレン−1−イル−2−オキソ−アセトアミド;
N−(2,5−ジ−tert−ブチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(3−アミノ−5−tert−ブチル−2−メトキシ−フェニル)−2−ナフタレン−1−イル−2−オキソ−アセトアミド;
5−tert−ブチル−N−エチル−3−{2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセチルアミノ}−2−メトキシ−ベンズアミド;
4−{2−[4−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イルアミノオキサリル)−ナフタレン−1−イル]−エチル}−ピペラジン−1−カルボン酸tert−ブチルエステル;
5−tert−ブチル−N−エチル−2−ヒドロキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−2−エトキシ−3−メタンスルホニルアミノ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N’−[1−(5−tert−ブチル−3−エチルカルバモイル−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(E)−イリデン]−ヒドラジンカルボキサミド;
2−{4−[2−(4−アセチル−ピペラジン−1−イル)−エトキシ]−ナフタレン−1−イル}−N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−アセトアミド;
5−tert−ブチル−N−エチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−安息香酸;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−[4−(2−ジメチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[4−(2−モルホリン−4−イル−ピリジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−チオフェン−2−カルボン酸アミド;
2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−N−m−トリル−アセトアミド;
5−tert−ブチル−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−チオフェン−2−カルボン酸メチルエステル;
N’−[1−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(Z)−イリデン]−ヒドラジンカルボキサミド;
N−[5−tert−ブチル−2−(3−メトキシ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−ピリジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−イソプロピル−2−p−トリル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(2−ベンゾイル−5−tert−ブチル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N−エチル−3−{2−ヒドラゾノ−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセチルアミノ}−2−メトキシ−ベンズアミド;
N−(5−tert−ブチル−3−エタンスルホニルアミノ−2−メトキシ−フェニル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−(3−アミノ−5−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−ジメチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−チオフェン−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(4−クロロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N’−[1−(5−tert−ブチル−3−カルバモイル−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(E)−イリデン]−ヒドラジンカルボキサミド;
N−[5−tert−ブチル−2−(4−メトキシ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[7−クロロ−4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−N−シクロプロピル−2−メトキシ−ベンズアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−{4−[2−(4−メチル−ピペラジン−1−イル)−エトキシ]−ナフタレン−1−イル}−2−オキソ−アセトアミド;
N−(5−tert−ブチル−チオフェン−3−イル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
5−tert−ブチル−N−シクロプロピル−3−[2−[(Z)−ヒドロキシイミノ]−2−(4−メトキシ−ナフタレン−1−イル)−アセチルアミノ]−2−メトキシ−ベンズアミド;
N−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イル)−2−[4−(4−モルホリン−4−イル−ピリミジン−2−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3−メトキシ−フェニル)−2H−ピラゾール−3−イル]−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−[2−メトキシ−5−(1−メチル−1−フェニル−エチル)−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−チオフェン−2−カルボン酸アミド;
5−tert−ブチル−N−イソブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(3,5−ジ−tert−ブチル−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセチルアミノ}−チオフェン−2−カルボン酸ジメチルアミド;
N−(5−tert−ブチル−2−メトキシ−3−メチル−フェニル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N’−[1−(5−tert−ブチル−3−シクロプロピルカルバモイル−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(E)−イリデン]−ヒドラジンカルボン酸エチルエステル;
N−インダン−5−イル−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3−クロロ−4−フルオロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−3−(イミダゾール−1−カルボニル)−2−メトキシ−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(2,4−ジフルオロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−オキソ−2−{4−[2−(5−オキソ−[1,4]ジアゼピン−1−イル)−エトキシ]−ナフタレン−1−イル}−アセトアミド;
N−(5−tert−ブチル−3−エタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
3−tert−ブチル−5−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ピラゾール−1−カルボン酸イソプロピルアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−アセトアミド;
N−[2−(3−アミノ−フェニル)−5−tert−ブチル−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
3−tert−ブチル−5−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ピラゾール−1−カルボン酸フェニルアミド;
N−(5−tert−ブチル−2−o−トリル−2H−ピラゾール−3−イル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[4−(2−モルホリン−4−イル−ピリミジン−4−イルオキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−チオフェン−2−カルボン酸アミド;
N−[5−tert−ブチル−2−(2,4−ジクロロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−イソオキサゾール−3−イル)−2−[4−(3−ヒドロキシ−プロポキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(3−tert−ブチル−イソオキサゾール−5−イル)−2−[(Z)−ヒドロキシイミノ]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−アセトアミド;
N−[5−tert−ブチル−2−メトキシ−3−(プロパン−1−スルホニルアミノ)−フェニル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−オキソ−2−{4−[2−(5−オキソ−[1,4]ジアゼピン−1−イル)−エトキシ]−ナフタレン−1−イル}−アセトアミド;
N−[5−tert−ブチル−2−(3−シアノ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−3−フェニルアセチルアミノ−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−3−{2−[4−(2−ジメチルアミノ−ピリミジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−チオフェン−2−カルボン酸アミド;
N’−[1−(5−tert−ブチル−3−エチルカルバモイル−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(E)−イリデン]−ヒドラジンカルボン酸エチルエステル;
N−(3−メタンスルホニルアミノ−5−トリフルオロメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−ヒドロキシ−3−ピペリジン−1−イルメチル−フェニル)−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−メトキシ−フェニル)−2−オキソ−2−{4−[2−((S)−1−フェニル−エチルアミノ)−ピリミジン−4−イルアミノ]−ナフタレン−1−イル}−アセトアミド;
N−[5−tert−ブチル−2−(4−シアノ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N’−[1−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニルカルバモイル)−1−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−メト−(E)−イリデン]−ヒドラジンカルボン酸エチルエステル;
N−(5−tert−ブチル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−フェニル)−イソブチルアミド;
N−[5−tert−ブチル−2−(4−メチル−ベンゾイル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(2−クロロ−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−(3−クロロ−4−メチル−フェニル)−2H−ピラゾール−3−イル]−2−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−[5−tert−ブチル−2−メトキシ−3−(プロパン−1−スルホニルアミノ)−フェニル]−2−[4−(2−モルホリン−4−イル−ピリジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
5−tert−ブチル−N−シクロプロピル−2−メトキシ−3−{2−[4−(2−モルホリン−4−イル−ピリジン−4−イルアミノ)−ナフタレン−1−イル]−2−オキソ−アセチルアミノ}−ベンズアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−オキソ−2−{4−[6−(テトラヒドロ−ピラン−4−イルアミノ)−ピリジン−3−イル]−ナフタレン−1−イル}−アセトアミド;
3−[2−(4−ブロモ−ナフタレン−1−イル)−2−オキソ−アセチルアミノ]−5−tert−ブチル−N−シクロプロピル−2−メトキシ−ベンズアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−[4−(6−モルホリン−4−イル−ピリジン−3−イル)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−2−p−トリル−2H−ピラゾール−3−イル)−2−[4−(6−モルホリン−4−イルメチル−ピリジン−3−イル)−ナフタレン−1−イル]−2−オキソ−アセトアミド;
N−(5−tert−ブチル−3−メタンスルホニルアミノ−2−メトキシ−フェニル)−2−オキソ−2−(4−ピリジン−3−イル−ナフタレン−1−イル)−アセトアミド;または
N−(5−tert−ブチル−2−メチル−2H−ピラゾール−3−イル)−2−オキソ−2−(4−ピリジン−3−イル−ナフタレン−1−イル)−アセトアミド
から選択される,請求項1記載の化合物。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50256903P | 2003-09-11 | 2003-09-11 | |
US60/502,569 | 2003-09-11 | ||
US53123403P | 2003-12-18 | 2003-12-18 | |
US60/531,234 | 2003-12-18 | ||
US57570404P | 2004-05-28 | 2004-05-28 | |
US60/575,704 | 2004-05-28 | ||
US58501204P | 2004-07-02 | 2004-07-02 | |
US60/585,012 | 2004-07-02 | ||
PCT/US2004/029372 WO2005023761A2 (en) | 2003-09-11 | 2004-09-10 | Cytokine inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007505127A JP2007505127A (ja) | 2007-03-08 |
JP2007505127A5 true JP2007505127A5 (ja) | 2007-10-25 |
JP4895811B2 JP4895811B2 (ja) | 2012-03-14 |
Family
ID=34280064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006526272A Expired - Fee Related JP4895811B2 (ja) | 2003-09-11 | 2004-09-10 | サイトカイン阻害剤 |
Country Status (12)
Country | Link |
---|---|
US (4) | US7749999B2 (ja) |
EP (1) | EP1670787B1 (ja) |
JP (1) | JP4895811B2 (ja) |
CN (1) | CN102060806A (ja) |
AU (1) | AU2004270733B2 (ja) |
BR (1) | BRPI0414313A (ja) |
CA (1) | CA2538820A1 (ja) |
HK (1) | HK1091210A1 (ja) |
IL (1) | IL174010A0 (ja) |
MX (1) | MXPA06002853A (ja) |
SG (1) | SG146624A1 (ja) |
WO (1) | WO2005023761A2 (ja) |
Families Citing this family (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
AU2004247626B8 (en) | 2003-05-15 | 2011-05-19 | Arqule, Inc. | Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38 |
BRPI0414313A (pt) * | 2003-09-11 | 2006-11-07 | Kemia Inc | inibidores de citocinas |
CN105820160B (zh) | 2003-11-05 | 2019-02-12 | 萨可德生物科学公司 | 细胞粘着调节剂 |
RU2006121990A (ru) | 2003-11-21 | 2007-12-27 | Эррэй Биофарма Инк. (Us) | Ингибиторы протеинкиназ акт |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US7829560B2 (en) | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
US8178672B2 (en) | 2004-10-19 | 2012-05-15 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase |
CA2589271A1 (en) | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
CA2589274A1 (en) | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2006091862A2 (en) * | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
WO2006099256A2 (en) * | 2005-03-11 | 2006-09-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
CA2610829A1 (en) * | 2005-06-14 | 2006-12-28 | Schering Corporation | The preparation and use of compounds as aspartyl protease inhibitors |
NZ564743A (en) * | 2005-07-11 | 2010-03-26 | Mitsubishi Tanabe Pharma Corp | An oxime derivative as a glucokinase activating agent and preparations thereof |
WO2007015877A2 (en) * | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
AU2006290442B2 (en) | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
WO2007035873A1 (en) * | 2005-09-21 | 2007-03-29 | Pharmacopeia, Inc. | Purinone derivatives for treating neurodegenerative diseases |
EP1933831A2 (en) | 2005-10-06 | 2008-06-25 | Vertex Pharmaceuticals, Inc. | Modulators of atp-binding cassette transporters |
US20100004248A1 (en) * | 2005-10-24 | 2010-01-07 | David Kass | Use of a Nitric Oxide Synthase Modulator for the Treatment of Cardiac Indications |
US20070243184A1 (en) * | 2005-11-08 | 2007-10-18 | Steven Fischkoff | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
WO2007058990A2 (en) * | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
WO2007075896A2 (en) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
ES2398319T3 (es) * | 2005-12-28 | 2013-03-15 | Vertex Pharmaceuticals Incorporated | Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística |
CN101415685B (zh) * | 2006-01-31 | 2011-08-24 | 阿雷生物药品公司 | 激酶抑制剂及其使用方法 |
KR101472248B1 (ko) | 2006-02-10 | 2014-12-16 | 서미트 코포레이션 피엘씨 | 뒤시엔느 근이영양증의 치료 |
US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
CA2644910C (en) | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
WO2007133614A2 (en) * | 2006-05-12 | 2007-11-22 | University Of Kentucky | Bis-quaternary ammonium cyclophane compounds that interact with neuronal nicotinic acetylcholine receptors |
JO3235B1 (ar) * | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
AU2007257959A1 (en) * | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
US20080064626A1 (en) * | 2006-09-08 | 2008-03-13 | Zanella John M | Methods of treating tendonitis in a subject by using an anti-cytokine agent |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
WO2008043031A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
AR063141A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
CA2669695C (en) * | 2006-11-13 | 2012-10-30 | Synta Pharmaceuticals Corp. | Tetrahydropyridinyl compounds for inflammation and immune-related uses |
US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
US8093246B2 (en) * | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
WO2008083124A1 (en) | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
WO2008084873A1 (ja) * | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
JP5207981B2 (ja) * | 2007-01-10 | 2013-06-12 | 田辺三菱製薬株式会社 | ヒドラゾン誘導体 |
WO2008089034A2 (en) * | 2007-01-11 | 2008-07-24 | Kemia, Inc. | Cytokine inhibitors |
DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
CN101687863B (zh) * | 2007-05-04 | 2012-09-12 | 阿斯利康(瑞典)有限公司 | 氨基-噻唑基-嘧啶衍生物及其治疗癌症的用途 |
US8563594B2 (en) | 2007-05-08 | 2013-10-22 | Allergan, Inc. | S1P3 receptor inhibitors for treating pain |
DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
WO2008147938A2 (en) * | 2007-05-24 | 2008-12-04 | Centocor, Inc. | Wnt5a as an inflammatory disease marker |
PE20090837A1 (es) | 2007-07-02 | 2009-07-24 | Boehringer Ingelheim Int | Nuevos compuestos quimicos |
SI2170396T1 (sl) * | 2007-08-03 | 2017-04-26 | Summit (Oxford) Limited | Kombinacije zdravil za zdravljenje duchennove mišične distrofije |
GB0715937D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment og duchenne muscular dystrophy |
ES2830024T3 (es) | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
JP2011516442A (ja) * | 2008-04-04 | 2011-05-26 | ビオマリン アイジーエー リミテッド | 筋ジストロフィーを治療するための化合物 |
CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
WO2009133834A1 (ja) * | 2008-04-28 | 2009-11-05 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有するケトアミド誘導体 |
CN102186809A (zh) | 2008-08-14 | 2011-09-14 | 拜尔农作物科学股份公司 | 杀虫性的4-苯基-1h-吡唑 |
CN102186856B (zh) | 2008-08-22 | 2014-09-24 | 诺华股份有限公司 | 作为cdk抑制剂的吡咯并嘧啶化合物 |
TW201014860A (en) | 2008-09-08 | 2010-04-16 | Boehringer Ingelheim Int | New chemical compounds |
CN102227421A (zh) | 2008-09-29 | 2011-10-26 | 贝林格尔.英格海姆国际有限公司 | 抗增殖化合物 |
WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
KR20100066868A (ko) * | 2008-12-10 | 2010-06-18 | 동화약품주식회사 | 신규한 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
KR20100066870A (ko) * | 2008-12-10 | 2010-06-18 | 동화약품주식회사 | 신규한 6-인다졸릴아미노-3-니트로피리딘 유도체 화합물, 그의 제조방법 및 이를 포함하는 약제학적 조성물 |
US20110306641A1 (en) * | 2008-12-10 | 2011-12-15 | Jei Man Ryu | Novel 2,6-substituted-3-nitropyridine derivative, method for preparing same, and pharmaceutical preparation including same |
KR20100067046A (ko) * | 2008-12-10 | 2010-06-18 | 동화약품주식회사 | 신규한 2,6―위치에 치환된 3―니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물 |
WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
WO2010094695A1 (en) | 2009-02-17 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases |
CA2757415C (en) | 2009-04-02 | 2018-02-06 | Merck Patent Gmbh | Autotaxin inhibitors |
JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ttk阻害作用を有するピリジンおよびピリミジン誘導体 |
WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
RU2602814C2 (ru) | 2009-09-25 | 2016-11-20 | Оризон Дженомикс С.А. | Лизинспецифические ингибиторы деметилазы-1 и их применение |
US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
EP2491033A4 (en) * | 2009-10-20 | 2013-03-13 | Eiger Biopharmaceuticals Inc | AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION |
US20110117055A1 (en) * | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
KR101924162B1 (ko) * | 2010-03-15 | 2018-11-30 | 버지니아 커먼웰스 유니버시티 | 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손 |
WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
JP5871896B2 (ja) | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | B−rafキナーゼインヒビター |
WO2011126903A2 (en) * | 2010-03-30 | 2011-10-13 | Verseon, Inc. | Multisubstituted aromatic compounds as inhibitors of thrombin |
HUE030938T2 (en) | 2010-04-19 | 2017-06-28 | Oryzon Genomics Sa | Lysine-specific demethylase-1 inhibitors and their use |
JP5904645B2 (ja) | 2010-05-07 | 2016-04-13 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | IL−1β関連病態の治療のための方法 |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
CN103124724B (zh) | 2010-07-29 | 2015-05-20 | 奥瑞泽恩基因组学股份有限公司 | Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途 |
WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
CN102093394B (zh) * | 2011-01-10 | 2012-11-21 | 中国药科大学 | 氯诺昔康氨丁三醇共晶 |
EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
US9006241B2 (en) | 2011-03-24 | 2015-04-14 | Noviga Research Ab | Pyrimidine derivatives |
RU2014105624A (ru) * | 2011-08-12 | 2015-09-20 | Ф. Хоффманн-Ля Рош Аг | Соединения индазола, способ их применения и фармацевтическая композиция |
RU2681211C2 (ru) | 2011-10-20 | 2019-03-05 | Оризон Дженомикс С.А. | (гетеро)арилциклопропиламины в качестве ингибиторов lsd1 |
BR112014009238B1 (pt) | 2011-10-20 | 2022-08-09 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina, seus usos e composições farmacêuticas |
US9044408B2 (en) | 2011-10-31 | 2015-06-02 | Avon Products, Inc. | Cosmetic use of N-heteroarylbisamide analogs and related compounds |
US9458154B2 (en) | 2011-12-09 | 2016-10-04 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
KR102477065B1 (ko) * | 2012-03-01 | 2022-12-13 | 어레이 바이오파마 인크. | 1-(3-tert-부틸-1-p-톨릴-1H-피라졸-5-일)-3-(5-플루오로-2-(1-(2-하이드록시에틸)-1H-인다졸-5-일옥시)벤질)우레아 하이드로클로라이드의 결정 형태 |
US20150202286A1 (en) * | 2012-07-13 | 2015-07-23 | The Children's Hospital of Philadelphai | Toxicity Management for Anti-Tumor Activity of CARs |
EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
US10548994B1 (en) * | 2013-03-11 | 2020-02-04 | Stc.Unm | Control of chronic neuropathic pain and allodynia |
US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9387250B2 (en) | 2013-03-15 | 2016-07-12 | Rutgers, The State University Of New Jersey | Therapeutic compositions for bone repair |
US9233961B2 (en) | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
NZ711064A (en) | 2013-03-15 | 2019-06-28 | Verseon Corp | Pyridone-substituted pyrazolyl compounds as serine protease inhibitors |
US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
CN110423221A (zh) | 2013-03-15 | 2019-11-08 | 维颂公司 | 作为凝血酶抑制剂的卤代吡唑 |
KR102340654B1 (ko) | 2013-04-02 | 2021-12-16 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제 |
CN103740734B (zh) * | 2013-07-01 | 2015-10-14 | 上海交通大学 | 厦门霉素生物合成基因簇、用途及菌株 |
DK3054936T5 (da) | 2013-10-10 | 2024-03-18 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer |
EA028819B1 (ru) | 2013-10-25 | 2018-01-31 | Новартис Аг | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
CN106029666B (zh) | 2013-12-19 | 2018-05-18 | 诺华股份有限公司 | 作为原生动物蛋白酶体抑制剂用于治疗寄生虫疾病例如利什曼病的[1,2,4]三唑并[1,5-a]嘧啶衍生物 |
CA2934199A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
NZ724250A (en) | 2014-03-07 | 2022-02-25 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
WO2015170218A1 (en) | 2014-05-07 | 2015-11-12 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
EP3172237A2 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016014535A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
WO2016044662A1 (en) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
EP3200786B1 (en) | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
HUE060104T2 (hu) | 2015-02-27 | 2023-01-28 | Verseon Int Corporation | Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
EP3344192A4 (en) | 2015-09-04 | 2019-05-15 | The Johns Hopkins University | INTERCANUAL DEVICE WITH LOW PROFILE |
US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
SG11201805300QA (en) | 2015-12-22 | 2018-07-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
MA44607A (fr) | 2016-04-06 | 2021-05-19 | Oxular Acquisitions Ltd | Inhibiteurs de kinase |
EP3452476B1 (en) | 2016-05-06 | 2021-12-15 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PT3472167T (pt) | 2016-06-20 | 2022-11-11 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JP2018052878A (ja) | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
JOP20190151B1 (ar) | 2016-12-20 | 2023-09-17 | Astrazeneca Ab | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
MA47120A (fr) | 2016-12-22 | 2021-04-28 | Incyte Corp | Dérivés pyridine utilisés en tant qu'immunomodulateurs |
MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
HUE060233T2 (hu) | 2016-12-22 | 2023-02-28 | Incyte Corp | Tetrahidro imidazo[4,5-c]piridin-származékok mint a PD-L1 internalizációját indukáló szerek |
GB201700257D0 (en) * | 2017-01-06 | 2017-02-22 | Atlantic Pharmaceuticals (Holdings) Ltd | New formulation |
PL3448859T3 (pl) | 2017-03-20 | 2020-02-28 | Forma Therapeutics, Inc. | Kompozycje pirolopirolu jako aktywatory kinazy pirogronianowej (PKR) |
CA3069720A1 (en) | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
CN114732910A (zh) | 2017-10-05 | 2022-07-12 | 弗尔康医疗公司 | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
MX2020006587A (es) | 2017-12-22 | 2020-12-10 | Ravenna Pharmaceuticals Inc | Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa. |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
DK3774791T3 (da) | 2018-03-30 | 2023-01-23 | Incyte Corp | Heterocykliske forbindelser som immunmodulatorer |
PT3790877T (pt) | 2018-05-11 | 2023-05-10 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1 |
JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Bcmaキメラ抗原受容体及びその使用 |
KR20210030947A (ko) * | 2018-07-03 | 2021-03-18 | 노파르티스 아게 | Nlrp3 길항제를 사용한 tnf 억제제 저항성 대상체를 위한 치료 방법 또는 치료제의 선택 방법 |
KR20210057014A (ko) * | 2018-09-13 | 2021-05-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | 이미다조피리디논 화합물 |
JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼrの活性化 |
US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
FI3860998T3 (fi) | 2018-10-05 | 2024-03-27 | Annapurna Bio Inc | Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon |
US11292782B2 (en) | 2018-11-30 | 2022-04-05 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
CN111825605B (zh) * | 2019-04-19 | 2023-03-31 | 中国科学院上海药物研究所 | 芳基酮酰胺类化合物及其制备方法和用途 |
WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
KR20220075382A (ko) | 2019-09-30 | 2022-06-08 | 인사이트 코포레이션 | 면역조절제로서의 피리도[3,2-d]피리미딘 화합물 |
AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
CR20230230A (es) | 2020-11-06 | 2023-07-27 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1693010A1 (de) | 1967-03-20 | 1971-07-22 | Ciba Geigy Ag | Oxalsaeurediamid-Derivate als Ultraviolett-Absorber |
GB1208015A (en) | 1967-03-23 | 1970-10-07 | Glaxo Lab Ltd | Cephalosporins |
US4029671A (en) | 1976-03-22 | 1977-06-14 | Eli Lilly And Company | 3-[(5-nitro-2-imidazolyl)pyrazol-5-yl]oxamic acid derivatives |
EP0122155A3 (en) * | 1983-04-12 | 1985-07-31 | Eli Lilly And Company | Improvements in or relating to naphthylglycyl cephalosporin derivatives |
IT1183181B (it) | 1985-02-07 | 1987-10-05 | Corvi Camillo Spa | Derivati del 3-metil-imidazo(4,5-c)pirazolo con attivita' terapeutica e procedimento per la loropreparazione |
US4761424A (en) | 1985-10-01 | 1988-08-02 | Warner-Lambert Company | Enolamides, pharmaceutical compositions and methods for treating inflammation |
LU87821A1 (fr) | 1990-10-12 | 1992-05-25 | Cird Galderma | Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique |
US5192770A (en) | 1990-12-07 | 1993-03-09 | Syntex (U.S.A.) Inc. | Serotonergic alpha-oxoacetamides |
FR2676439B1 (fr) | 1991-05-13 | 1994-10-28 | Cird Galderma | Nouveaux composes bi-aromatiques derives d'un motif salicylique, leur procede de preparation et leur utilisation en medecine humaine et veterinaire ainsi qu'en cosmetique. |
JPH05201980A (ja) | 1992-01-30 | 1993-08-10 | Mitsubishi Kasei Corp | メトキシイミノ酢酸誘導体およびこれを有効成分とする農園芸用殺菌剤 |
US6750207B1 (en) | 1992-05-01 | 2004-06-15 | Yeda Research And Development Co. Ltd. | Compositions for the regulation of cytokine activity |
FR2713637B1 (fr) | 1993-12-15 | 1996-01-05 | Cird Galderma | Nouveaux composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
JPH07224041A (ja) | 1994-02-10 | 1995-08-22 | Mitsubishi Chem Corp | ピラゾリル酢酸誘導体およびこれを有効成分とする農園芸用殺菌剤 |
US5624957A (en) | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
DE19636150A1 (de) | 1996-09-06 | 1998-03-12 | Asta Medica Ag | N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung |
US6143931A (en) | 1997-04-16 | 2000-11-07 | Arqule, Inc. | Synthesis and use of α-ketoamide derivatives and arrays |
AU7135598A (en) | 1997-04-16 | 1998-11-11 | Arqule, Inc. | Synthesis and use of biased arrays |
AU7129098A (en) | 1997-04-16 | 1998-11-11 | Arqule, Inc. | Synthesis and use of alpha-ketoamide derivatives and arrays |
JP2001521934A (ja) | 1997-11-03 | 2001-11-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬としての芳香族ヘテロ環式化合物 |
US6358506B1 (en) | 1997-11-05 | 2002-03-19 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
PT1042305E (pt) | 1997-12-22 | 2005-10-31 | Bayer Pharmaceuticals Corp | Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas |
EP1043995B9 (en) | 1997-12-22 | 2008-10-08 | Bayer Pharmaceuticals Corp. | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
DE19814838C2 (de) | 1998-04-02 | 2001-01-18 | Asta Medica Ag | Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung |
ES2262072T3 (es) | 1998-04-28 | 2006-11-16 | Elbion Ag | Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4. |
WO1999064044A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Novel therapeutic agents that modulate 5-ht receptors |
US6197750B1 (en) | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
AU6056599A (en) | 1998-09-24 | 2000-04-10 | Bristol-Myers Squibb Company | Active enantiomer of rargamma-specific agonist |
DK1115707T3 (da) | 1998-09-25 | 2004-03-01 | Astrazeneca Ab | Benzamidderivater og deres anvendelse som cytokininhibitorer |
AU6060099A (en) | 1998-09-30 | 2000-04-17 | Procter & Gamble Company, The | 2-substituted ketoamides |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
EP1022027A1 (en) | 1999-01-22 | 2000-07-26 | Applied Research Systems ARS Holding N.V. | Tumor necrosis factor antagonists and their use in endometriosis |
CA2360934A1 (en) | 1999-02-22 | 2000-08-31 | Lin-Hua Zhang | Polycyclo heterocyclic derivatives as antiinflammatory agents |
GB9905579D0 (en) | 1999-03-12 | 1999-05-05 | Secr Defence | Photoactive pentaerythritol derivatives and orientation layers |
ATE303357T1 (de) | 1999-03-17 | 2005-09-15 | Amid-derivate | |
JP2001031636A (ja) | 1999-05-18 | 2001-02-06 | Senju Pharmaceut Co Ltd | α−ケトアミド誘導体およびその医薬用途 |
ATE323482T1 (de) | 1999-07-02 | 2006-05-15 | Stuart A Lipton | Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten |
CA2374737C (en) | 1999-07-09 | 2008-02-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
AU6387500A (en) | 1999-08-05 | 2001-03-05 | Procter & Gamble Company, The | Multivalent exocyclic diketo compounds |
EE200200065A (et) | 1999-08-12 | 2003-04-15 | Pharmacia Italia S.P.A. | 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon |
GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
US6492393B1 (en) | 1999-11-16 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
IT1315267B1 (it) | 1999-12-23 | 2003-02-03 | Novuspharma Spa | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale |
DE19962300A1 (de) | 1999-12-23 | 2001-06-28 | Asta Medica Ag | Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
PE20010830A1 (es) | 2000-01-28 | 2001-09-06 | Syngenta Ltd | Derivados de azol insecticidas o fungicidas y composiciones que los comprenden |
WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
NZ521389A (en) | 2000-03-14 | 2005-06-24 | Upjohn Co | 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds |
DE10034880A1 (de) | 2000-07-18 | 2002-02-07 | Siemens Ag | Dosiersystem |
IT1318641B1 (it) | 2000-07-25 | 2003-08-27 | Novuspharma Spa | Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale. |
EP1337250A2 (en) | 2000-10-19 | 2003-08-27 | SmithKline Beecham Corporation | Use of p38 inhibitors for the treatment of smoke inhalation |
TWI262920B (en) * | 2000-10-27 | 2006-10-01 | Elbion Ag | New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them |
EP1341782A2 (en) | 2000-11-20 | 2003-09-10 | Scios Inc. | Inhibitors of p38 kinase |
GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
JP2004518739A (ja) | 2001-02-15 | 2004-06-24 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症剤として有用なヘテロアリール置換尿素化合物の合成方法 |
GB2373245A (en) | 2001-03-12 | 2002-09-18 | Bayer Ag | Pyridinyl pyrazoles and their use for the treatment of COPD |
CA2443697A1 (en) | 2001-04-13 | 2002-10-24 | Pier F. Cirillo | 1,4-disubstituted benzo-fused compounds |
JP2004530690A (ja) | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
EP1395561A1 (en) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
ATE338035T1 (de) | 2001-06-05 | 2006-09-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen |
EP1405852B9 (en) | 2001-06-20 | 2013-03-27 | Daiichi Sankyo Company, Limited | Diamine derivatives |
ATE401079T1 (de) | 2001-06-29 | 2008-08-15 | Ab Science | Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen |
US7005081B2 (en) * | 2001-07-05 | 2006-02-28 | Canon Kabushiki Kaisha | Base material cutting method, base material cutting apparatus, ingot cutting method, ingot cutting apparatus and wafer producing method |
CA2453147A1 (en) | 2001-07-11 | 2003-01-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
ES2312603T3 (es) | 2001-07-24 | 2009-03-01 | Richter Gedeon Nyrt | Derivados de piperidina como antagonistas del receptor nmda. |
CA2454913A1 (en) | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin |
WO2003022273A1 (en) | 2001-09-13 | 2003-03-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
CA2462441A1 (en) | 2001-10-18 | 2003-04-24 | Pier F. Cirillo | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
US6562558B1 (en) | 2001-12-06 | 2003-05-13 | Eastman Kodak Company | Photographic element, compound, and process |
WO2003049742A1 (en) | 2001-12-11 | 2003-06-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for administering birb 796 bs |
FR2834288B1 (fr) | 2001-12-28 | 2011-12-16 | Virbac Sa | Procede de preparation de nouveaux derives n-substitues de 5-amino-phenylpyrazole, nouveaux derives n-substitues de 5-amino-phenylpyrazole et leur utilisation comme agents parasiticides et/ou insecticides |
US20040023961A1 (en) | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
US20030236277A1 (en) | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
ES2299689T3 (es) | 2002-02-25 | 2008-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas. |
US20030225089A1 (en) | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
EP1499898A2 (en) | 2002-04-19 | 2005-01-26 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
JP2003335733A (ja) | 2002-05-14 | 2003-11-28 | Sugai Chemical Industry Co Ltd | 1,4−アミノナフトール誘導体の製造方法 |
DE60310730T2 (de) | 2002-07-09 | 2007-05-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
US20040044020A1 (en) | 2002-07-09 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors |
KR20050026095A (ko) | 2002-08-01 | 2005-03-14 | 엘비온 아게 | 고도로 순수한 하이드록시 인돌릴 글리옥실산 아미드의제조 방법 |
US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
DE10241407A1 (de) | 2002-09-06 | 2004-03-18 | Elbion Ag | Behandlung nicht allergischer Rhinitis durch selektive Phosphodiesterase 4-Hemmstoffe |
US7115644B2 (en) | 2002-09-13 | 2006-10-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds |
MXPA05002745A (es) | 2002-09-13 | 2005-06-03 | Synta Pharmaceuticals Corp | Sintesis de indolizinas. |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
WO2004058724A1 (ja) | 2002-12-25 | 2004-07-15 | Sumitomo Chemical Company, Limited | フェニルピラゾール化合物及びそれを用いた植物病害の防除方法 |
WO2004078116A2 (en) | 2003-03-03 | 2004-09-16 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
WO2004083193A1 (ja) | 2003-03-17 | 2004-09-30 | Sumitomo Chemical Company, Limited | アミド化合物およびこれを含有する殺菌剤組成物 |
BRPI0414313A (pt) * | 2003-09-11 | 2006-11-07 | Kemia Inc | inibidores de citocinas |
JP4635013B2 (ja) * | 2004-02-10 | 2011-02-16 | グラフィック パッケージング インターナショナル インコーポレイテッド | 開口及び位置決め機構を有するカートン |
-
2004
- 2004-09-10 BR BRPI0414313-2A patent/BRPI0414313A/pt not_active IP Right Cessation
- 2004-09-10 JP JP2006526272A patent/JP4895811B2/ja not_active Expired - Fee Related
- 2004-09-10 AU AU2004270733A patent/AU2004270733B2/en not_active Ceased
- 2004-09-10 EP EP04809707A patent/EP1670787B1/en active Active
- 2004-09-10 WO PCT/US2004/029372 patent/WO2005023761A2/en active Application Filing
- 2004-09-10 CN CN2010105398924A patent/CN102060806A/zh active Pending
- 2004-09-10 CA CA002538820A patent/CA2538820A1/en not_active Abandoned
- 2004-09-10 SG SG200806677-1A patent/SG146624A1/en unknown
- 2004-09-10 US US10/939,324 patent/US7749999B2/en not_active Expired - Fee Related
- 2004-09-10 MX MXPA06002853A patent/MXPA06002853A/es active IP Right Grant
-
2006
- 2006-02-28 IL IL174010A patent/IL174010A0/en unknown
- 2006-11-20 HK HK06112755.4A patent/HK1091210A1/xx not_active IP Right Cessation
-
2009
- 2009-12-14 US US12/637,714 patent/US7897599B2/en not_active Expired - Fee Related
- 2009-12-14 US US12/637,712 patent/US7919617B2/en not_active Expired - Fee Related
-
2010
- 2010-07-02 US US12/829,701 patent/US20100273797A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007505127A5 (ja) | ||
US7749999B2 (en) | Alpha-ketoamides and derivatives thereof | |
CA2732806A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
ES2154253T3 (es) | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. | |
ES2153340T3 (es) | Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas. | |
US6150385A (en) | 1,3,4-thiadiazoles useful for the treatment of CMV infections | |
JP5562859B2 (ja) | 電位開口型ナトリウムチャネルの阻害剤として有用なアリールアミド | |
CA2582029A1 (en) | Aryl nitrogen-containing bicyclic compounds and methods of use | |
JP2012515724A5 (ja) | ||
CA2641453C (en) | Thiadiazole derivatives for the treatment of neuro degenerative diseases | |
US20120149706A1 (en) | Inhibition of p38 kinase activity using substituted heterocyclic ureas | |
JP2011500598A (ja) | 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド | |
AU2008252068B2 (en) | Inhibition of Raf Kinase Using Substituted Heterocyclic Ureas | |
HRP20130972T1 (hr) | Premošteni derivati spiro [2,4] heptana kao alx-receptori i/ili fprl2-agonisti | |
PT1725544E (pt) | 3-[4-heterociclil-1,2,3-triazol-1-il]-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crónicas | |
WO2007058990A2 (en) | Therapy using cytokine inhibitors | |
RU2008129129A (ru) | Пиперазины и пиперидины в качестве mglur5 потенцирующих средств | |
RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
JP2013517273A5 (ja) | ||
RU2005128833A (ru) | Замещенные сульфамидами производные ксантина для применения в качестве ингибиторов фосфоенолпируваткарбоксикиназы (рерск) | |
CA2497448A1 (en) | Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions | |
ZA200602080B (en) | Cytokine inhibitors | |
JP2001114690A (ja) | p38MAPキナーゼ阻害剤 | |
RU2006106849A (ru) | Ингибиторы цитокинов | |
US20100184774A1 (en) | Methods of treatment |